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CORONARY ARTERY DISEASE IN METABOLIC SYNDROME: A ROLE FOR THE 
SARCOPLASMIC RETICULUM Ca2+ ATPASE 
  
 Coronary artery disease (CAD) is a leading cause of death among Americans 
and is fueled by underlying metabolic syndrome (MetS). The prevalence and lethality of 
CAD necessitates rigorous investigations into its underlying mechanisms and to facilitate 
the development of effective treatment options. Coronary smooth muscle (CSM) 
phenotypic modulation from quiescent to synthetic, proliferative, and osteogenic 
phenotypes is a key area of investigation, with underlying mechanisms that remain 
poorly understood. Using a well-established pre-clinical model of CAD and MetS, the 
Ossabaw miniature swine, we established for the first time the time course of Ca2+ 
dysregulation during MetS-induced CAD progression. In particular, we used the 
fluorescent Ca2+ dye, fura-2, to examine alterations in CSM intracellular Ca2+ regulation 
during CAD progression, as perturbations in intracellular Ca2+ regulation are implicated 
in several cellular processes associated with CAD pathology, including CSM contractile 
responses and proliferative pathways. These studies revealed that the function of 
several CSM Ca2+ handling proteins is elevated in early CAD, followed by loss of 
function in severe atherosclerotic plaques. Decreased intracellular Ca2+ regulation 
occurred concurrently with reductions in CSM proliferation, measured with Ki-67 
staining. In particular, alterations in sarcoplasmic reticulum (SR) Ca2+ store together with 
altered function of the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) were 
associated with induction of proliferation. Organ culture of coronary arterial segments 
revealed that culture-induced medial thickening was prevented by SERCA inhibition with 
cyclopiazonic acid (CPA). Activation of SERCA with the small molecule activator, 
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CDN1163, increased CSM proliferation, which was attenuated by treatment with CPA, 
thus establishing upregulated SERCA function as a proximal inducer of CSM 
proliferation. Further, we demonstrated that in vitro treatment of CSM from lean 
Ossabaw swine with the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, 
increased SERCA function. However, in vivo treatment of Ossabaw swine with MetS 
with the GLP-1 receptor agonist, AC3174, had no effect on CAD progression and in vitro 
examination revealed resistance of SERCA to GLP-1 receptor agonism in MetS. These 
findings further implicate SERCA in CAD progression. Collectively, these are the first 
data directly linking SERCA dysfunction to CSM proliferation and CAD progression, 
providing a key mechanistic step in CAD progression. 
Michael Sturek, Ph.D., Chair 
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CHAPTER 1: INTRODUCTION 
Obesity 
Currently, nearly 35% of adults in the United States are obese, as shown by a 
body mass index (BMI) ≥ 30 kg/m2 (1). Globally, in 2014 39% of adults were overweight 
(BMI ≥ 25 kg/m2) and obesity affected 11% of men and 15% of women (2). Even in 
developing countries, well-meaning philanthropic efforts have increased supply of 
sweeteners and oils and have unfortunately contributed to global rises in obesity (3). In 
addition to the vast numbers of adults suffering from obesity, nearly 17% of children in 
the United States are classified as obese (1). Worldwide, the proportion of overweight 
and obese children has increased from 5% in 2000 to 9% in 2014 (2). Juvenile obesity is 
of special concern because during childhood obesity occurs through both adipocyte 
hyperplasia and hypertrophy (4), while in adults obesity occurs primarily through 
adipocyte hypertrophy (5). The presence of adipocyte hyperplasia in childhood indicates 
that juvenile obesity actually increases potential for greater obesity in adulthood. In 
addition to the rising numbers of obese individuals, we must contend with ever-
increasing medical costs. Obesity alone is estimated to cost the United States $147 
billion in medical costs (6). 
 An understanding of the origins of obesity provides clues to potential underlying 
mechanisms of disease etiology. During the early hunter-gatherer phase of human 
evolution our species was exposed to the “feast or famine” food availability associated 
with seasonal cycles. This environment served as the selective pressure by which the 
“thrifty genotype” was propagated. During times of plenty, the thrifty genotype enabled 
efficient storage of excess calories in various fat depots (7). These fat depots could then 
be mobilized as energy sources during “famine” times, when food supply was restricted. 
Modern food preservation options have eliminated the cyclical pattern of food availability, 
providing a constant, plentiful supply. Today, a sedentary lifestyle combined with 
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abundant food supply renders this “thrifty genotype” harmful (8). We live in an 
“obesogenic environment” of constant “feast,” signaling our bodies to build fat depots. In 
the absence of “famine,” these fat depots continue to grow unchecked, resulting in 
growing waistlines and many obesity-related complications (9). 
Metabolic Syndrome 
Closely related to the obesity crisis is an ever-increasing incidence of metabolic 
syndrome (MetS). Alberti et al. (10) defines the word “syndrome” as “simply a clustering 
of factors that occur together more often than by chance alone and for which the cause 
is often uncertain.” Using this definition of “syndrome,” MetS is easily defined as a 
clustering of metabolic conditions, all of which are risk factors for cardiovascular disease 
or diabetes. Because of the vague nature of these definitions, there has been much 
disagreement regarding proper criteria for diagnosis. Beginning with World Health 
Organization (WHO) consortium in 1998 (11), attempts have been made to reconcile 
differences in diagnostic criteria. The most recent standard for diagnosis is the presence 
of 3 of the 5 risk factors listed in Table 1.1 (10; 12). Hypertension and insulin resistance 
are also often included as independent risk factors in the diagnosis of MetS (11). Indeed 
both insulin resistance and glucose intolerance contribute to the hyperglycemia shown in 
Table 1.1. 
In addition to the thrifty genotype hypothesis surrounding development of obesity 
and MetS, a “thrifty phenotype” hypothesis has also been proposed (13; 14) which states 
that, during fetal and early postnatal development, undernutrition may trigger fetal 
programming of adaptive mechanisms. These fetal adaptations are rendered harmful 
when the postnatal environment is healthy and nutrition is adequate. Whether inherited 
(thrifty genotype hypothesis), or environmentally triggered (thrifty phenotype hypothesis), 
a propensity toward MetS may contribute to overall decline of metabolic health and lead 
to additional complications, including diabetes and cardiovascular disease. 
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Although many controversies exist surrounding the development and 
components of MetS, it is well-established that the presence of MetS confers elevated 
risk for the development of diabetes and cardiovascular disease. Indeed, the presence 
of MetS doubles risk of cardiovascular disease development (10; 15-17). While each 
component of MetS is an individual risk factor for cardiovascular disease, the presence 
of the MetS cluster confers greater risk than any individual component (18). Risk for 
developing type 2 diabetes mellitus is increased 5 times by presence of MetS (10). 
Ultimately, MetS increases risk of all-cause mortality 1.5-fold (17).  
Several animal models have been developed to recapitulate many of the risk 
factors for MetS. The Ossabaw miniature swine is an excellent model for MetS, as they 
display a “thrifty phenotype,” and naturally develop all of the human risk factors for MetS. 
Table 1.2 (adapted from (19)) describes Ossabaw miniature swine as a superior model 
of MetS compared to Yucatan miniature swine, which are leaner and are resistant to 
development of MetS. 
Type 2 Diabetes 
In 2011, 366 million individuals worldwide were affected by diabetes mellitus 
(20), defined by the American Diabetes Association as “a group of metabolic diseases 
characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, 
or both (21).” Diabetes mellitus is sub-classified into two forms: Type 1 diabetes mellitus 
that is initiated through an auto-immune attack on the β-cells of the endocrine pancreas 
resulting in diminished insulin production, while type 2 diabetes mellitus is a progressive 
disease, resulting from prolonged glucose intolerance and insulin resistance, and 
accounts for 90-95% of diabetes mellitus cases in North America (22). Diabetes mellitus 
cost the United States $245 billion in 2012 in direct and indirect medical costs (23; 24). 
The etiology of type 2 diabetes mellitus is complex, often riddled with other 
confounding metabolic factors. In normal physiology, a post-prandial rise in plasma 
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glucose is sensed by the pancreatic beta cell, and insulin secretion is initiated. 
Circulating insulin binds to receptors on peripheral tissues (liver, skeletal muscle, 
adipose), initiating intracellular signaling cascades resulting in glucose uptake. In early 
type 2 diabetes mellitus (Fig. 1.1) (25), elevated fasting blood glucose levels result from 
reduced insulin sensitivity in the peripheral tissues. This reduced sensitivity occurs 
through multiple signaling pathways, including a lack of receptor binding of insulin or 
through aberrant post-receptor signaling in the peripheral tissues. The incidence of 
insulin resistance is elevated with increasing age, obesity, and a sedentary lifestyle. The 
resultant rise in plasma glucose sparks a compensatory rise in insulin secretion, giving 
rise to the hyperinsulinemia closely associated with the etiology of type 2 diabetes 
mellitus. Over time, as insulin sensitivity decreases, the ever-increasing demand on the 
pancreatic beta cell for more insulin creates an impossible feed-forward loop. The beta 
cell, unable to compensate for the growing demands, can no longer produce adequate 
insulin and ultimately fails.  
Many options exist for the treatment of type 2 diabetes mellitus (26; 27). In 
addition to initial recommendations for diet modification and exercise, most individuals 
diagnosed with type 2 diabetes mellitus are also treated with glucose-lowering drugs. 
This can be accomplished through insulin-sensitization (biguanides) (28-30), 
enhancement of insulin secretion from the pancreatic beta cell (sulfonylureas) (31; 32), 
or through combined increase of insulin sensitivity and insulin secretion (glucagon-like 
peptide-1 receptor agonists) (33; 34). Following beta cell failure, insulin therapy is often 
necessary.  
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Coronary Circulation 
One of the major long-term complications of poorly controlled type 2 diabetes is 
coronary artery disease, which ultimately causes the greatest morbidity and mortality in 
type 2 diabetes patients. Accordingly, fundamental knowledge of the regulation of the 
coronary circulation in health and disease is essential. 
 The coronary arteries branch from the proximal aorta, wrapping around the heart 
and branching deep into the myocardium. The coronary circulation delivers oxygen and 
other substrates to the tirelessly working heart. Because resting myocardial oxygen 
consumption is high, its oxygen delivery must be efficient. Hindrances to coronary blood 
flow can have far-reaching and serious consequences.  
The right and left main coronary arteries originate from the left and right ostia 
(Fig. 1.2; (35)) in the proximal aorta, just distal to the aortic semilunar valve. The left 
main coronary artery branches soon after leaving the ostium into the left anterior 
descending (LAD) artery, and the circumflex (CFX) artery. The LAD travels along the 
anterior interventricular groove, while the CFX wraps around the heart in the left 
atrioventricular groove. The right coronary artery (RCA) wraps around the heart in the 
right atrioventricular groove. In ~90% of humans (right-dominant), once the RCA reaches 
the posterior interventricular groove, it turns downward, becoming the posterior 
descending artery (35). In the remaining ~10% (left-dominant), the CFX becomes the 
posterior descending artery. 
The coronary arteries can be subdivided into macrovascular conduit coronary 
arteries (described above), and microvascular resistance arterioles (36). The large 
conduit coronary arteries branch extensively, giving rise to first, second, and third order 
resistance arterioles. These branches dive deep into the myocardium, providing the tight 
control over blood flow necessary to regulate substrate delivery to the myocardium. 
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Histological examinations reveal the cell types and extracellular matrix of the 
conduit coronary artery (Fig. 1.3). Arteries are comprised of three layers, the adventitia, 
the media, and the intima. The adventitial layer, comprised primarily of collagen and 
other connective tissue, provides the tough outer layer surrounding most arteries. The 
medial layer comprises the bulk of the artery wall and is composed primarily of vascular 
smooth muscle. The intimal layer lies adjacent to the lumen and is comprised primarily of 
a single layer of endothelial cells. The media is bounded by two layers of elastin, termed 
the internal elastic lamina between the media and the intima and the external elastic 
lamina between the media and the adventitia. Resistance arterioles are primarily 
comprised of a medial layer, which provides them the ability for the tight regulation of 
circumference necessary to regulate blood flow to the myocardium. 
Coronary Artery Disease 
 Cardiovascular disease accounted for 23.6% of all deaths in the United States in 
2012 (37), maintaining its rank as the leading cause of death. Incidence of 
cardiovascular disease is predicted to rise to 40.5% of the United States population by 
2030 (38). Estimated costs for cardiovascular disease in the United States from 2011-
2012 were $316.6 billion, including both direct and indirect medical costs (6). These 
totals have significantly decreased since 2006, when cardiovascular disease medical 
costs were estimated at $403.1 billion (39). 
 Coronary artery disease (CAD) is one of the many forms of cardiovascular 
disease. An estimated 15.5 million adults in the United States suffer from CAD and 1 out 
of every 7 deaths has CAD as an underlying cause (6). The etiology and progression of 
CAD is complex and still under investigation. In 1995, Stary et al. (40) introduced a 
system for the classification of CAD stages (detailed in Fig. 1.4, edited from (41; 42)). In 
the early, clinically insignificant stages of CAD, fatty streaks develop as lipids infiltrate 
the intimal region of the coronary artery. CAD progresses with recruitment of circulating 
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leukocytes from the bloodstream and of coronary smooth muscle (CSM) cells from the 
medial layer of the artery. Further progression of CAD involves apoptosis, leading to the 
accumulation of lipids and cellular debris within the core of the atherosclerotic plaque. 
Plaques with large lipid-laden and/or necrotic cores and thin fibrous caps (types 4-6) are 
prone to rupture, resulting in thrombosis, embolism, and acute myocardial infarction. The 
current understanding of the cellular biology underlying atherosclerosis has recently 
been summarized in excellent reviews by Tabas et al. (43) and McEvoy et al. (42). 
The relationship between MetS and CAD is both complicated and convincing. 
Lakka et al. (44) examined development of CAD in 1,209 Finnish middle-aged men over 
the course of 11 years. None of the patients displayed cardiovascular disease at the 
beginning of the study. The presence of MetS significantly increased incidence of CAD. 
The presence of MetS not only increases risk of CAD, but also increases CAD severity 
(18). In one study of 632 individuals, multivariate analysis revealed that, as the number 
of MetS components present increased, severity of CAD, as assessed by Gensini 
scoring, was elevated (45) (Fig. 1.5). Gensini scoring assigns values for CAD severity 
based on the amount of stenosis and the “importance” of the location of the 
atherosclerotic lesion in the coronary anatomy (e.g.: a lesion in the left main coronary 
artery would affect more myocardium than would a lesion in the distal LAD and would be 
assigned a higher score) (45). Ultimately, MetS exacerbates both risk for and severity of 
CAD, presenting a variety of targets for CAD treatment and prevention. Type 2 diabetes 
also contributes to CAD risk; however, the focus of this work will be on the role of MetS 
in CAD development. 
Vascular Smooth Muscle 
 CSM cells play a key role in CAD progression, functioning both in plaque 
stabilization and outward remodeling to maintain arterial lumen diameter. Smooth 
muscle cells are generally small (diameter ~5-6 µm) with an elongated spindle-shape 
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(length ~20-50 µm) and display profound heterogeneity in both cellular and molecular 
physiology. First, depending on location and function, smooth muscle may display either 
phasic (non-vascular and some venous smooth muscle, such as in the portal vein) or 
tonic (most vascular) contraction patterns (36; 46; 47). Vascular smooth muscle (VSM) 
must sustain some level of tone throughout the life of the organism, while 
gastrointestinal smooth muscle must participate in peristaltic contractions. These 
differences in function highlight the need for differential contraction patterns. The focus 
here will be on VSM, and in particular, coronary smooth muscle (CSM). 
 The most dramatic difference in the subcellular organization of smooth muscle as 
compared to striated muscle is the lack of organized contractile filament sarcomeres. 
Rather, thin filaments attach at the sarcolemma to membrane plaques and within the 
cytosol to “floating” dense bodies, which are analogous to the z-lines in striated muscle 
(36; 48; 49). These thin filaments associate with myosin filament groups to form “mini-
sarcomeres” (49). The thin filaments are composed primarily of actin and tropomyosin, 
which course along in a lattice arrangement (36), which has shown ability to rapidly 
adapt, providing the wide working length range necessary in smooth muscle (50; 51). 
Smooth muscle cells are connected to one another by gap junctions, forming a 
functional syncytium (36; 49). This coupling allows ion flow from one cell to the next, 
resulting in the concerted, controlled contraction and relaxation necessary to modulate 
blood flow. Smooth muscle, contracting together, result in reduction in arterial diameter, 
which restricts blood flow. Simultaneous, controlled relaxation of smooth muscle results 
in arterial dilation, which increases blood flow. This ability is crucial to the organism’s 
ability to modulate substrate delivery according to specific need. 
Excitation-Contraction (E-C) coupling may occur in smooth muscle via two 
different mechanisms: electromechanical coupling and pharmacomechanical coupling 
(49), both functioning through a rise in cytosolic Ca2+ to trigger contraction. 
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Electromechanical coupling evokes contraction through changes in membrane potential, 
such as membrane depolarization. Pharmacomechanical coupling refers to any E-C 
coupling event which evokes contraction independent of alterations in membrane 
potential, i.e. largely without depolarization. The trigger for this kind of E-C coupling is 
either ligand-gated Ca2+ influx, intracellular Ca2+ release, or modulation of the Ca2+ 
sensitivity of the contractile proteins (49). Physiologically, electromechanical and 
pharmacomechanical coupling often occur in concert (52; 53), providing the CSM means 
by which to obtain greater contraction or relaxation than would be possible with only one 
stimulus.  
Smooth Muscle Phenotypic Modulation 
 Under normal, healthy conditions, CSM cells maintain a quiescent, contractile 
phenotype. However, under conditions of vascular injury or atherosclerotic CAD, CSM 
cells will modulate phenotype to respond to the changing environment. Identification of 
phenotypic markers has proven difficult, because smooth displays remarkable diversity, 
and because many markers of smooth muscle differentiation are also expressed in other 
cell types (54). Still, a variety of markers have been identified. In addition to the normal, 
quiescent phenotype, two primary abnormal phenotypes have been described - the 
proliferative CSM and the osteogenic CSM.  
The first abnormal CSM phenotype, proliferative CSM is implicated in a variety of 
disease states, and functions in CAD progression both to stabilize atherosclerotic plaque 
and in lumen expansion via outward arterial remodeling. Experimental identification of 
proliferative CSM is difficult. However, based on observations in cell culture, proliferative 
CSM cells do not express normal contractile proteins (49; 55). Thus, identification of the 
proliferative CSM phenotype can be done by observation of the loss of a number of 
contractile CSM markers, such as smooth muscle myosin heavy chain (SM-MHC), 
smoothelin, smooth muscle α-actin, or calponin. Additionally, proliferative smooth muscle 
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cells possess the ability to secrete elevated amounts of collagen and other extracellular 
matrix proteins, which functions to assist in atherosclerotic plaque stabilization. 
The second abnormal CSM phenotype is the osteogenic smooth muscle 
phenotype. These CSM underlie arterial calcification, expelling molecules, largely by 
secretion of matrix vesicles (exosomes) to form hydroxyapatite crystals (56). Osteogenic 
CSM cells, like proliferative CSM cells, lack markers of mature, contractile CSM, such as 
SM-MHC (57). However, unlike proliferative CSM, osteogenic CSM express bone 
marker proteins, such as runt-related transcription factor-2 (RUNX2) (57). Calcification 
during CAD progression most often occurs in the neointimal layer of coronary arteries, 
while calcification induced by kidney disorders most often occurs within the arterial 
media (56; 57). The detailed mechanisms underlying calcification are still under 
investigation. While the experiments contained in this thesis do not directly examine 
coronary artery calcification, it is likely that perturbations in CSM intracellular Ca2+ 
regulation contribute to the phenotypic switch to an osteogenic phenotype, and future 
studies will undertake the establishment of these links.  
Coronary Smooth Muscle Intracellular Ca2+ Regulation 
In CAD, the Ca2+ handling mechanisms in CSM cells are profoundly altered. 
Intracellular Ca2+ is a ubiquitous second messenger and regulator of a number of critical 
processes in CSM cells, including excitation-contraction coupling, excitation-transcription 
coupling, and proliferation. Therefore, a variety of Ca2+ handling proteins are employed 
to keep cytoplasmic Ca2+ under tight regulation (Fig. 1.6), to maintain average 
cytoplasmic Ca2+ concentration at ~100 nM. Ca2+ regulating proteins can be loosely 
divided into three categories: cytoplasmic Ca2+ binding proteins, such as calmodulin, 
membrane bound Ca2+ transporting proteins, and sarcoplasmic reticulum (SR) Ca2+ 
binding proteins, such as calreticulin and calsequestrin. The membrane bound Ca2+ 
transporting proteins function to bring Ca2+ into the CSM cells from the extracellular 
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environment (influx mechanisms), transport Ca2+ out of the cytosol to the extracellular 
environment (efflux mechanisms), transport Ca2+ into intracellular Ca2+ stores from the 
cytosol, and transport Ca2+ out of the cytosol into intracellular Ca2+ stores.  
Ca2+ influx mechanisms are mediated by voltage-gated Ca2+ channels (VGCC) 
and transient receptor potential (TRP) channels. VGCCs are controlled by membrane 
potential and open in response to membrane depolarization. These channels are the 
target of many blood pressure lowering, arrhythmia correcting drugs, such as verapamil, 
nifedipine, and diltiazem. Inhibition of VGCCs results in attenuation of contraction, thus 
maintaining lower arterial pressures. In contrast, TRP channels mediate store-operated 
Ca2+ entry (SOCE), which partly compensates for depletion of internal Ca2+ stores (58). 
Following both VGCC and TRP channel opening, Ca2+ enters the CSM cells passively, 
flowing down its electrochemical gradient. 
Ca2+ efflux involves active transport, as Ca2+ moves out of the CSM cell against 
its electrochemical gradient. The Na+/Ca2+ exchanger (NCX) harvests the energy from 
the movement of two Na2+ ions flowing down their gradient into the CSM, and transports 
a single Ca2+ ion out of the CSM cell. The plasmalemma Ca2+ ATPase (PMCA) uses the 
energy gained by ATP hydrolysis to pump Ca2+ out of the CSM cell. 
Alterations in SR Ca2+ beyond an optimal set point likely play a pivotal role in SR 
CSM phenotypic modulation during CAD progression. Internal Ca2+ stores serve a 
crucial role in CSM Ca2+ regulation, providing the bulk of the Ca2+ required for CSM 
contraction. The SR occupies 1-7.5% of cell volume in smooth muscle (49), and is the 
primary intracellular Ca2+ store, contiguous with the nuclear envelope. Additionally, 
interactions between SR and mitochondrial Ca2+ stores have been observed, with 
mitochondria contributing to SR Ca2+ refilling following SR Ca2+ store depletion (59), 
although details of this mechanism remain unknown. Total SR luminal Ca2+ 
concentrations are estimated to be 2-5 mM (60) with the majority of luminal Ca2+ bound 
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by SR Ca2+-binding proteins, such as calreticulin and calsequestrin. Luminal free [Ca2+] 
fluctuates with store filling and depletion, and estimates in non-smooth muscle cells 
suggest that luminal free [Ca2+] ranges from 60-400 µM in the full state to 1-50 µM in the 
depleted state (61). The tight regulation of SR [Ca2+] is necessary for healthy CSM 
function. Studies in cardiac muscle reveal that overloading of the SR with Ca2+ results 
overload-induced Ca2+ store release (62), resulting in cardiac arrhythmias. Early studies 
from our lab in CSM indicate a similar phenomenon, termed SR Ca2+ unloading (63-65). 
While much of this “unloaded” Ca2+ may be preferentially released toward the 
sarcolemma for extrusion (63-65), other studies in SMC monolayer cultures indicate that 
increased SR Ca2+ stores are responsible for the elevations in bulk cytosolic Ca2+ 
necessary for induction of SMC de-differentiation and proliferation (66-68). Therefore, 
elevated luminal SR Ca2+ results in loss of the differentiated, contractile phenotype, 
leading to the increased CSM proliferation observed in early CAD. Conversely, 
decreases in SR luminal Ca2+ are sensed by Ca2+ binding chaperones within the SR, 
such as Grp78, which trigger induction of endoplasmic reticulum stress pathways, which, 
if unchecked, result in apoptosis (61). Thus, CSM apoptosis induced by reductions in SR 
Ca2+ store may contribute to the increased necrotic core observed in advanced 
atherosclerotic lesions in late CAD.  
Two Ca2+ release channels, located in the contiguous sarcoplasmic reticulum 
(SR) and nuclear envelope membranes, are responsible for release of Ca2+ from the 
internal store; however, the results of release are wildly divergent. Ryanodine receptors 
(RyR), while important in striated muscle for Ca2+ induced Ca2+ release and muscle 
contraction, have a lesser role in initiating contraction of CSM. In the CSM, localized 
Ca2+ sparks resulting from RyR release of SR Ca2+ elicits spontaneous transient outward 
K+ currents, hyperpolarizing the sarcolemma, closing VGCCs, and ultimately relaxing the 
CSM (36; 69). Conversely, the release of Ca2+ that is mediated by inositol 1,4,5-
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trisphosphate (IP3) receptors is mediated through hormone binding to G protein coupled 
receptors. Activation of the hormone receptor results in phospholipase C cleavage of 
phosphatidylinositol diphosphate, liberating IP3. Liberated IP3 functions, in part, to initiate 
Ca2 release from the SR through IP3 receptors located on the SR membrane. While 
RyRs are the primary means of Ca2+-induced Ca2+ release, IP3 activity is largely 
mediated by contracting factors from the coronary endothelium, such as endothelin-1 
(70). 
A major mechanism of relaxation of CSM is mediated through Ca2+ uptake by the 
sarco-endoplasmic reticulum Ca2+ ATPase (SERCA). Using energy gained from ATP 
hydrolysis, SERCA pumps Ca2+ out of the cytosol into the SR, thus removing the 
stimulus for contraction, ultimately resulting in relaxation. The affinity of SERCA for Ca2+ 
is regulated by phospholamban. Phosphorylation of phospholamban results in its 
dissociation from SERCA, leading to an increased affinity of SERCA for Ca2+, and 
efficient removal of Ca2+ from the cytosol. The phosphorylation of phospholamban is 
mediated through the activity of cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate – dependent protein kinases. 
Mammalian SERCA 1, 2, and 3 are homologous proteins encoded by three 
distinct genes (71). Alternative splicing of these genes results in more than ten 
mammalian SERCA isoforms. Broadly, SERCA1 is primarily expressed in skeletal 
muscle, SERCA2 is ubiquitously expressed, and SERCA3 is expressed primarily in non-
muscle cells. Alternative splicing of SERCA2 results in three distinct SERCA2 isoforms. 
SERCA2a is largely expressed in cardiac and slow-twitch skeletal muscle (71), although 
recent studies have implicated loss of SERCA2a in VSM as a potential contributor to 
proliferation in arterial organ culture conditions (72-74). SERCA2b is ubiquitously 
expressed, both in muscle and non-muscle cells (71). SERCA2c was more recently 
identified in cardiac muscle (75). 
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In CAD, almost all of these described Ca2+ handling mechanisms are altered. 
Table 1.2 summarizes the changes in intracellular Ca2+ handling with diabetic 
dyslipidemia or MetS-induced CAD. However, there are several discrepancies in the 
literature regarding these changes in Ca2+ handling. In particular, there is disagreement 
regarding the up- vs. downregulation of VGCC and SERCA function. Several studies by 
our research group have demonstrated increased VGCC function and expression in 
CAD (76-78), while additional studies from ours and other groups have shown 
decreased VGCC function in CAD (79; 80). We have demonstrated both increased (79; 
81) and decreased (82) SERCA function in CAD. Differences in breed, MetS/CAD 
duration, and systemic milieu (i.e. diabetic dyslipidemia vs. MetS) between studies 
demonstrate the need for studies in a common animal model examining alterations in 
Ca2+ handling during CAD/MetS progression, linking these changes to specific facets of 
CAD progression. 
Glucagon-like Peptide-1 Actions on the Coronary Vasculature 
Modulation of intracellular Ca2+ handling processes is hypothesized to result in 
prevention of CSM phenotypic switching, disallowing CAD progression. Thus, efforts 
toward drug discovery and development to this end are crucial. Glucagon-like peptide-1 
(GLP-1) is an endogenous hormone, secreted in a postprandial manner, which functions 
to increase insulin sensitivity and to increase insulin biosynthesis and secretion (33). The 
GLP-1 receptor is a G protein-coupled receptor activated upon ligand binding. Several 
downstream intracellular signaling pathways have been implicated in the propagation of 
GLP-1 receptor activation. The most well characterized of the GLP-1 receptor pathways 
is as follows: GLP-1 receptor activation results in the generation of cAMP by adenylate 
cyclase (83; 84), triggering the activation of protein kinase A (PKA) (85), which has a 
number of phosphorylation targets, including VGCCs (86; 87) and the negative regulator 
of SERCA, phospholamban (88; 89). Additional pathways have also been elucidated, 
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including phosphatidylinositol 3-kinase activation of extracellular signal-related kinase 
(ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) (90; 91), or protein kinase 
Cζ (PKCζ) (92), and through activation of PLC (84). 
Endogenous, native GLP-1 is rapidly degraded by dipeptidyl-peptidase IV (DPP-
IV) (93; 94). Because of this rapid degradation, GLP-1 demonstrates a half-life in vivo of 
~1-2 minutes (94). Thus, a number of DPP-IV resistant GLP-1 analogs and GLP-1 
receptor agonists were developed for therapeutic use. The discovery of DPP-IV resistant 
Exendin-4 in the saliva of Heloderma suspectum (95), and its verification as a GLP-1 
receptor agonist (96) and insulinotropic agent (97; 98), triggered the synthesis of a 
number of GLP-1 receptor agonists which are resistant to cleavage by DPP-IV. 
Currently, there are five GLP-1 receptor agonists approved for treatment of type 2 
diabetes, and variations in the structure of these synthetic agonists contribute to 
variations in half-life and dosing interval (99). Exenatide was the first of GLP-1 receptor 
agonist to be developed and approved for use in humans, and continues to be used both 
in treatment of patients and in basic research (100-102). A number of other agonists are 
in various phases of development, and are used in basic research. For example, 
AC3174 demonstrates similar pharmacokinetic and pharmacodynamics profiles as 
exenatide, and has been used in a number of basic research studies (34; 103; 104).  
 Early studies of GLP-1 activity in the pancreatic β-cell revealed a role for GLP-1 
receptor modulation of intracellular Ca2+ handling, resulting in heightened glucose-
stimulated insulin secretion (105). Specifically, GLP-1 receptor agonists increase Ca2+ 
current through VGCCs, both through plasma membrane depolarization resulting from 
inhibition of KATP channels (106-108) and through increased VGCC sensitivity to a 
depolarizing event (105; 109). Further, GLP-1 receptor activation assists in mobilization 
of internal Ca2+ stores via both IP3R and RyR activation (110; 111). Thus, GLP-1 
receptor activation in pancreatic β-cells contributes to enhanced glucose-stimulated 
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insulin secretion through elevations in cytosolic Ca2+ by increasing both Ca2+ influx 
across the plasma membrane and by increasing release of internal Ca2+ stores.  
GLP-1 receptor agonists have also garnered much interest as potential 
cardioprotective agents. Indeed, exenatide has been demonstrated to reduce myocardial 
infarct size following ischemia/reperfusion injury in swine (112). Exendin-4 was shown to 
protect against neointimal thickening following vascular injury (113). AC3174 improved 
cardiac function and remodeling during chronic heart failure (103) and partially relieved 
hypertension in rats (104). GLP-1 receptor agonists have also demonstrated a number 
of intracellular and Ca2+ handling effects, signaling both through ERK1/2 and cAMP 
pathways to reduce endoplasmic reticulum stress in macrophages (114) and 
cardiomyocytes (115), in part through increased SERCA function and/or protein 
expression. Further, GLP-1 receptor agonists enhance SERCA function in vascular 
endothelial cells (116). Thus, GLP-1 has potential for a protective role in the coronary 
vasculature. In this thesis, we examined the effect of GLP-1 receptor agonists on MetS-
induced CAD progression, and on CSM intracellular Ca2+ handling in health and 
MetS/CAD. 
The prevalence and severity of obesity, MetS, and T2D, and their contribution to 
CAD incidence and severity necessitate detailed investigation into the underlying 
mechanisms propagating this deadly disease cocktail. This thesis work tackles an 
examination of CSM Ca2+ handling changes during the progression of CAD, specifically 
dissects a causal role for SERCA in CSM proliferation, and examines the effect of a 
specific glucose-lowering agent on SERCA function in health and MetS/CAD. 
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Major Hypotheses 
1. Intracellular CSM Ca2+ handling, specifically SR Ca2+ buffering by SERCA, is 
increased in early MetS/CAD and decreased in late MetS/CAD. This pattern in SR Ca2+ 
buffering is paralleled by changes that occur in CSM proliferation during CAD 
progression. 
2. Acute SERCA activation increases the SR Ca2+ store and causes CSM proliferation, 
consistent with increased SR Ca2+ contribution to CSM proliferation in early stages of 
CAD. 
3. Metabolic syndrome confers cardiovascular resistance to GLP-1 receptor agonism, 
and this effect is mediated, at least in part, by lack of SERCA responsiveness to GLP-1 
receptor activation.  
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Tables and Figures 
 
Figure 1.1: A time course of type 2 diabetes mellitus progression in humans (25). 
A. Fed and fasting plasma glucose levels become elevated prior to diabetes diagnosis 
(“prediabetes” or “metabolic syndrome”) at “Time 0.” B. Insulin resistance, together with 
the elevated plasma glucose levels in panel A, initiate compensatory elevations in beta 
cell function. However, with prolonged insulin resistance and hyperglycemia, the over-
worked beta cells fail, resulting in drastically decreased insulin production.  
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Figure 1.2: Anatomy of the coronary circulation (35). LA = Left atrium; CFX = 
Circumflex artery; LAD = Left anterior descending artery; LV = Left ventricle; IVV = 
Interventricular vein; RV = Right ventricle; RCA = Right coronary artery; RA = Right 
atrium; PV = Posterior vein; PDA = Posterior descending artery. 
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Figure 1.3: Cross-sectional anatomy of a coronary artery. The coronary artery is 
comprised of three main regions: the intima, the media, and the adventitia. The media is 
bounded by two elastic lamina: the internal elastic lamina and the external elastic 
lamina. On the luminal side of the internal elastic lamina, the intimal layer contains 
primarily endothelial cells. The media is comprised primarily of smooth muscle cells and 
extracellular matrix proteins, such as collagen. On the outer side of the external elastic 
lamina is the protective adventitial layer, comprised of collagen and various other 
extracellular matrix proteins. 
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Figure 1.4: A time course of coronary artery disease progression (Adapted from 
(41; 42)). Following initial insult, recruitment of circulating leucocytes, deposition of 
lipids, and initiation of smooth muscle cell proliferation initiates the coronary artery 
disease (CAD) cascade, beginning with a thin fatty streak (Type 2 lesions). Cholesterol 
deposits are engulfed by infiltrated macrophages, thus forming foam cells. Type 3 
atherosclerotic lesions are characterized by aggregation of foam cells, together with 
induction of CSM proliferation and migration into the forming atherosclerotic lesion. As 
CAD progresses into type 4 and 5 atherosclerotic lesions, proliferative CSM secrete 
extracellular matrix proteins to stabilize the growing lesion. Further lipid and foam cell 
accumulation, together with apoptosis of CSM and other cell types initiate the formation 
of a necrotic lipid core. Additionally, the deposition of hydroxyapatite crystals into the 
plaque contributes to coronary artery calcification, which, in early microcalcification 
stages, can serve to de-stabilize the growing plaque. Thin-walled, necrotic atheromas 
are susceptible to rupture, resulting in acute myocardial infarction. 
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Figure 1.5: Metabolic syndrome increases severity of coronary artery disease in 
an additive fashion (45). Metabolic syndrome (MetS) scores were assigned to 632 
patients, based on the number of MetS risk factors present (0-5). CAD severity was 
assessed in each of these cases, using the Gensini scoring system. The Gensini scoring 
system classifies severity based on the extent of luminal narrowing, as well as the 
location of the atherosclerotic lesion. Lesions with greater luminal narrowing, and in 
“crucial” regions, such as the left main coronary artery, receive higher Gensini scores. 
Gensini scores were increased in a “dose-dependent” manner with increasing number of 
MetS risk factors. 
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Figure 1.6: Membrane-bound Ca2+ regulatory proteins in coronary smooth muscle. 
Influx mechanisms include voltage-gated Ca2+ channels (VGCC) and transient receptor 
potential (TRP) channels. Efflux mechanisms include the plasma membrane Ca2+ 
ATPase (PMCA) and the sodium-calcium exchanger (NCX). Sarcoplasmic reticulum 
(SR) Ca2+ release channels include the ryanodine receptor (RyR) and the inositol 1,4,5-
trisphosphate receptor (IP3R). Ca2+ is returned to the SR via the sarco-endoplasmic 
reticulum Ca2+ ATPase (SERCA). 
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Table 1.1: Criteria for Clinical Diagnosis of the Metabolic Syndrome† 
Component Term Categorical Cutoff 
Elevated waist circumference Abdominal Obesity 
Men Women 
≥102 cm ≥88 cm 
Elevated fasting triglycerides Dyslipidemia ≥ 150 mg/dL ≥ 150 mg/dL 
Reduced high-density lipoprotein 
cholesterol Dyslipidemia <40 mg/dL <50 mg/dL 
Elevated blood pressure Hypertension ≥130/85 
mmHg 
≥130/85 
mmHg 
Elevated fasting plasma glucose Hyperglycemia ≥100 mg/dL ≥100 mg/dL 
†Adapted from Alberti et al. (10) 
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Table 1.2: Comparison of metabolic syndrome in Yucatan and Ossabaw swine† 
Component Yucatan Ossabaw References 
Obesity No Yes (76; 82; 91; 117-155) 
Insulin resistance No Yes 
(82; 117; 124-126; 128; 129; 
132-140; 142; 144; 147; 152; 
155-160) 
Glucose intolerance No Yes 
(76; 79; 82; 117; 118; 121; 
122; 124-127; 129; 132-137; 
139; 140; 143; 146; 147; 
152; 154; 156; 158-163) 
Dyslipidemia (↑LDL/HDL) Yes Yes 
(76; 79; 82; 91; 117; 119; 
122; 123; 125; 126; 134-136; 
138; 139; 141; 142; 151; 
152; 155; 156; 159; 161; 
162; 164-167) 
Dyslipidemia (↑ triglycerides) No Yes 
(81; 91; 117; 122-126; 132; 
134-136; 139; 140; 143; 152; 
154-156; 159-161; 163; 165; 
167) 
Hypertension No Yes 
(76; 91; 119; 122; 124-127; 
129; 134-136; 139; 143; 152; 
155; 158) 
†Adapted from Sturek et al. (19)  
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Table 1.3: Changes in Intracellular Ca2+ Handling in Coronary Artery Disease 
Ca2+ Transporter Change in Function References 
Voltage-gated Ca2+ channel (VGCC) ↑,↓ (76-80; 168) 
Transient receptor potential channel (TRP) ↑ (79; 126) 
Na+/Ca2+ Exchanger (NCX) ↓ (79; 82; 160) 
Plasmalemma Ca2+ ATPase (PMCA) ↓ (79; 82; 160) 
Sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) ↑,↓ (79; 82; 160) 
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CHAPTER 2: BIPHASIC ALTERATIONS IN CORONARY SMOOTH MUSCLE Ca2+ 
REGULATION IN A REPEAT CROSS-SECTIONAL STUDY OF CORONARY ARTERY 
DISEASE SEVERITY IN METABOLIC SYNDROME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Published in Atherosclerosis 249:1-9, 2016.  
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Abstract 
Background and Aims 
Coronary artery disease (CAD) is progressive, classified by stages of severity. 
Alterations in Ca2+ regulation within coronary smooth muscle (CSM) cells in metabolic 
syndrome (MetS) have been observed, but there is a lack of data in relatively early (mild) 
and late (severe) stages of CAD. The current study examined alterations in CSM Ca2+ 
regulation at several time points during CAD progression.  
Methods 
MetS was induced by feeding an excess calorie atherogenic diet for 6, 9, or 12 months 
and compared to age-matched lean controls. CAD was measured with intravascular 
ultrasound (IVUS). Intracellular Ca2+ was assessed with fura-2. 
Results 
IVUS revealed that the extent of atherosclerotic CAD correlated with the duration on 
atherogenic diet. Fura-2 imaging of intracellular Ca2+ in CSM cells revealed heightened 
Ca2+ signaling at 9 months on diet, compared to 6 and 12 months, and to age-matched 
lean controls. Isolated coronary artery rings from swine fed for 9 months followed the 
same pattern, developing greater tension to depolarization, compared to 6 and 12 
months (6 months= 1.8 ± 0.6 g, 9 months= 5.0 ± 1.0 g, 12 months= 0.7 ± 0.1 g). CSM in 
severe atherosclerotic plaques showed dampened Ca2+ regulation and decreased 
proliferation compared to CSM from the wall.  
Conclusion 
These CSM Ca2+ regulation data from several time points in CAD progression and 
severity help to resolve the controversy regarding up- vs. down-regulation of CSM Ca2+ 
regulation in previous reports. These data are consistent with the hypothesis that 
alterations in sarcoplasmic reticulum Ca2+ contribute to progression of atherosclerotic 
CAD in MetS.  
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Background 
Obesity affects more than one-third of adults in the United States (1). The human 
propensity for obesity has been attributed to a “thrifty genotype” (7). This “thrifty 
genotype” was adaptive during the early stages of human evolution, when humans were 
easily affected by the “feast or famine” environment associated with changing seasons 
and a lack of modern food preservation and storage. Now, a consistent and abundant 
food supply, coupled with a sedentary lifestyle, has propelled the obesity epidemic, 
resulting in the coining of such terms as “obesogenic environment” (9) and tongue-in-
cheek references to a new species with the name “Homo sedentarius” (8). Obesity often 
appears in connection with the metabolic syndrome (MetS), which is classically defined 
as the clustering of three or more of the following risk factors: central obesity, 
hypertension, dyslipidemia, insulin resistance, and glucose intolerance (169). Together, 
obesity and MetS double the risk of coronary artery disease (CAD), the leading killer of 
Americans (15).  
CAD is a progressive disease with stages typically classified according to the 
Stary classification system (40). Early, clinically insignificant neointimal thickening due to 
lipid deposition in the artery wall worsens with increasing lipid and inflammatory cell 
infiltration (170; 171). Further progression involves recruitment of coronary smooth 
muscle (CSM) cells from the media into the growing plaque. Such mobilization is 
accompanied by a shift in CSM phenotype from healthy, contractile CSM cells to 
synthetic, proliferative CSM cells (54), whose secretory capabilities result in the 
deposition of collagen and other fibers into the developing lesion. The presence of CSM 
cells in the atherosclerotic plaque stabilizes the early lesion. As atherosclerotic CAD 
progresses, however, increased apoptosis and accumulation of lipids and cellular debris 
within the plaque results in thinning of the fibrous cap surrounding the lesion. This 
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thinning of the fibrous cap may lead to rupture and thrombosis, often resulting in 
myocardial infarction and sudden cardiac death. 
Ca2+ is a ubiquitous second messenger known to be involved in smooth muscle 
contraction (54; 172), proliferation (54; 173-175), migration (176; 177), and gene 
transcription (178; 179). Therefore, alteration in CSM Ca2+ regulation in CAD is an 
important area of study. Alterations in many Ca2+ transporters, including voltage-gated 
Ca2+ channels (76; 79), sarco-endoplasmic reticulum Ca2+ ATPases (79; 81; 82), 
transient receptor potential channels (126), plasma membrane Ca2+ ATPases (79), and 
Na+/Ca2+ exchangers (79), have been described in CAD (180). However, there is a 
paucity of data regarding time-dependent changes in CSM Ca2+ handling in the setting of 
obesity/MetS. This study utilized the well-characterized Ossabaw miniature swine model 
of MetS and CAD (19; 82; 125; 126; 136; 181) to examine the changes in CSM Ca2+ 
regulation during obesity-induced CAD progression, providing a much needed 
longitudinal assessment of Ca2+ regulation over time and with increasing severity. 
Further, we examined differences in Ca2+ regulation in CSM harvested specifically from 
plaque vs. vascular wall.  
Methods 
Animal care and experimental groups 
All experimental procedures involving animals were approved by the Institutional 
Animal Care and Use Committee at Indiana University School of Medicine with the 
recommendations outlined by the National Research Council and the American 
Veterinary Medical Association Panel on Euthanasia (182; 183). Six month old Ossabaw 
miniature swine were fed 1 kg of an excess-calorie atherogenic diet daily for 6 (n=6), 9 
(n=7), or 12 (n=9) months in the repeat cross-sectional study (Figs. 2.1 and 2.2). The 6 
and 9 month time points were considered “early” and the 12 month time point “late” CAD 
for comparison to Lean healthy pigs. For comparison, an additional subset of Ossabaw 
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miniature swine were fed the same excess-calorie atherogenic diet above for 11 months 
to provide coronary arteries for comparison of CSM in “mild CAD” and “severe CAD” 
defined as arteries with less than 30% and greater than 30% plaque burden, 
respectively, as assessed by IVUS (Figs. 2.3-2.5). Plaque vs. vascular wall components 
were dissected from the same artery segments in severe CAD to compare CSM 
properties (Fig. 2.4). Lean control swine for this dataset (n=6) were fed the standard diet 
mentioned above. 
 Metabolic Phenotyping 
 Final body weights and blood were obtained at time of sacrifice for lipid analysis 
(ANTECH Diagnostics, Fishers, IN). 
Intravascular ultrasound (IVUS) for quantification of coronary artery disease 
Swine were anesthetized and intravascular ultrasound was performed as 
described previously (82; 126; 139; 148).  
Still frame IVUS pullback images were obtained offline at 1 mm intervals (Fig. 
2.1). Percent plaque burden measures were obtained using Image J software (1.48v, 
National Institutes of Health, USA).  
Fluorescent imaging for assessment of CSM intracellular Ca2+ signaling from freshly 
harvested coronary arteries 
CSM cells from Ossabaw swine were enzymatically isolated from freshly 
dissected coronary arteries and loaded with fura-2 AM (2.5 mmol/l Molecular Probes, 
Life Technologies, Eugene, OR) as previously described (79; 82; 126; 184).  
Isometric tension studies for functional assessment of freshly harvested coronary 
arteries 
Isometric tension was examined in isolated coronary artery rings (2-4 mm in 
length) as described previously (141).  
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Isolation of atherosclerotic plaques from coronary arteries with severe CAD 
 Following IVUS and sacrifice, coronary arteries were excised and cleaned of 
adherent tissue. Arteries were segmented and opened longitudinally. Artery segments 
with plaque burden greater than 30% as measured by IVUS were selected and labeled 
as “severe CAD” (n=5). Plaques such as those labeled as intima (I) in Fig. 2.4I “Severe 
CAD” histology were trimmed away from the artery wall and placed in conical tubes 
containing the same collagenase solution previously described for isolation of CSM cells 
from the coronary artery wall (media) (79; 82; 126; 184). The plaque cell population was 
then isolated through a series of enzymatic washes. Plaque cells were loaded with fura-
2/AM for 45 minutes, washed, and placed on ice prior to being imaged as described 
above. 
Histology 
Coronary artery segments (2-4 mm in length) were placed in 10% phosphate-
buffered formalin for 24-48 hours, and then transferred to 70% ethanol. Histology was 
performed in the Department of Anatomy and Cell Biology at Indiana University School 
of Medicine (Indianapolis, IN).  
Immunohistochemistry 
Coronary artery segments embedded in paraffin (described above) were 
transported the Department of Pathology at Indiana University School of Medicine and 
were processed as previously described (139). Immunostaining was performed using Ki-
67 as a proliferation marker. Images were captured using a LEICA DM 300 inverted 
microscope and analyzed with ImageJ software. 
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Statistical Analysis 
 Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). 
One-way analysis of variance (ANOVA) or two-way ANOVA with Bonferroni post hoc 
analysis was performed. Data are represented as mean ± SEM. p<0.05 was considered 
statistically significant. 
Results 
Metabolic Characteristics 
 Swine fed an excess-calorie atherogenic diet developed MetS as indicated by 
increased body weight, hypertension, and elevated total cholesterol and triglycerides, 
(see Table 1 in associated Data in Brief article (185)). Plasma triglycerides and total 
cholesterol were decreased at 12 months of diet in the initial, repeat cross-sectional 
study. In contrast, total cholesterol was not different between mild and severe CAD 
groups in the 11-month diet study (data not shown). 
Coronary artery disease (CAD) severity increases during prolonged MetS duration. 
 Analysis of IVUS still-frames revealed increased coronary artery plaque burden 
MetS swine with time on atherogenic diet (Fig. 2.1D), but did not significantly increase 
until 12 months on diet. Percent wall coverage increased early in MetS-induced CAD, 
plateauing later (Fig. 2.1D; Solid line), indicating that atherosclerotic plaques expand 
around the circumference of the artery prior to encroachment upon the lumen. These 
data support our statement that percent wall coverage is a strong tool for quantification 
of early intimal CAD prior to the stage of more intimal plaque burden. These 
quantification methods suggest that swine on 6-9 months of atherogenic diet present 
with “early stage” CAD (representative IVUS still frame in Fig. 2.1B), whereas 12 months 
on atherogenic diet results in “late stage” CAD (representative still frame in Fig. 2.1C). 
Coronary smooth muscle Ca2+ responses to depolarization are biphasically altered 
during disease progression. 
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Fura-2/AM assessment of intracellular Ca2+ handling in response to 
depolarization revealed a biphasic pattern in CSM from swine with MetS, in which 
responses were heightened in “early state” CAD, followed by dampened responses in 
“late stage” CAD. Fig. 2.2A provides a representative tracing to demonstrate the 
experimental protocol. CSM from swine with “early stage” CAD after nine months of 
atherogenic feeding demonstrated greater Ca2+ influx through voltage-gated Ca2+ 
channels (VGCC) after activation by K+ (80 mmol/l; Green shading; Fig. 2.2A) compared 
to cells from age-matched lean swine as quantified by area under the curve. This 
increased VGCC activation was absent in CSM from swine with “late stage” CAD (Fig. 
2.2B).  
Coronary artery responses to depolarization are biphasically altered during disease 
progression. 
 Functional assessment of coronary rings from lean pigs revealed no effect of age 
on tension development to KCl (20 mM) (Fig. 2.2C; Black Bars). Rings from swine with 
MetS revealed a biphasic change in tension development to 20 mM KCl as CAD 
progressed (Fig. 2.2C; White Bars). When compared to age-matched leans, rings from 
swine with “early stage” CAD after 9 months of atherogenic feeding developed 
significantly more tension to KCl (20 mM). Following 12 months of atherogenic diet 
feeding, tension development dramatically decreases below that of rings from lean age-
matched swine (Fig. 2.2C). 
Sarcoplasmic reticulum Ca2+ store capacity is altered during CAD progression. 
Release of the SR store with caffeine (5 mmol/l)-triggered activation of ryanodine 
receptors is observed as a transient, robust increase in cytosolic [Ca2+] (Blue Arrow; Fig. 
2.2A). This transient increase was significantly greater in CSM from swine with “early 
stage” CAD compared to CSM from age-matched lean swine. As observed with 
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depolarization responses, this increased Ca2+ signal in CSM from swine with “early 
stage” CAD was absent in CSM from swine with “late stage” CAD (Fig. 2.2D).  
Recovery of cytosolic [Ca2+] following SR Ca2+ store release is biphasically altered 
during CAD progression 
Finally, Ca2+ buffering impairment along with simultaneously store-operated Ca2+ 
influx was assessed after SR store depletion. This is observed as a sustained Ca2+ 
signal above baseline levels following SR Ca2+ store depletion with caffeine (Red Arrow; 
Fig. 2.2A). While this revealed the same pattern of Ca2+ alterations during the time 
course of CAD progression, no significant changes from age-matched lean swine were 
observed (Fig. 2.2E).  
Plaque burden and collagen content are increased with CAD severity 
Arteries with greater than 30% plaque burden as assessed by IVUS were 
classified as having “severe” CAD, while arteries with less than 30% plaque burden were 
classified as having “mild” CAD. To further classify disease severity for more detailed 
analysis of plaque composition, histological analysis was performed. See lumen (L), 
intima (I), and media (M) layers labeled in Fig. 2.3A-C. Plaque burden in the “severe 
CAD” group was increased compared to that in the “mild CAD” group (Fig. 2.3G). An 
additional measure of intimal plaque growth is obtained when the intimal/medial area 
ratio (I/M) is assessed. I/M was significantly increased in severe CAD, compared to mild 
(Fig. 2.3H). Further, to assess progression of plaque fibrosis, collagen content within the 
plaque was examined and was increased ~30% in severe disease, compared to mild 
(Fig. 2.3I). Medial collagen content trended toward increase with severe CAD, but this 
was not significant (Fig. 2.3J; p = 0.08). 
Sarcoplasmic reticulum Ca2+ handling is altered with CAD severity 
To examine steady-state SR [Ca2+], the SR Ca2+ store was released with caffeine 
(5 mmol/l) in the absence of extracellular Ca2+ (See Fig. 2.4A for representative 
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tracing/experimental protocol; “Caf-sensitive SR Ca2+ store”; bi-directional arrow) and the 
transient increase in cytosolic [Ca2+] was measured. In CSM isolated from arterial 
segments with mild CAD a dramatic increase in caffeine-sensitive steady-state SR [Ca2+] 
was observed (Fig. 2.4B). In contrast, CSM isolated from plaques of arteries with severe 
CAD showed depletion of the caffeine-sensitive steady-state SR [Ca2+] compared to 
CSM isolated from both healthy and mild CAD swine. Following an increase in cytosolic 
[Ca2+] resulting from caffeine stimulation, a number of extrusion/buffering mechanisms 
are employed to restore cytosolic [Ca2+]. SERCA buffering activity is assessed by 
measuring the cytosolic [Ca2+] undershoot below baseline levels during recovery from 
caffeine stimulation (see Fig. 2.4A; “SERCA Activity”; downward arrow). The cytosolic 
[Ca2+] undershoot (SERCA activity) was increased in mild CAD and was dramatically 
decreased in CSM of arterial segments from severe CAD (Fig. 2.4C).  
To provide an intra-arterial comparison, intracellular Ca2+ regulation in CSM 
harvested specifically from the intima (plaque) region was compared to CSM from the 
wall (media) of arteries with severe CAD. The caffeine-sensitive steady-state SR Ca2+ 
store was depleted in CSM from intima (plaque) compared to CSM from the artery wall 
(media) (Fig. 2.4D). Correspondingly, when CSM from the intima (plaque) was 
compared with the adjacent artery wall (media), plaque cells demonstrated a decreased 
undershoot, i.e. decreased SERCA activity (Fig. 2.4E). 
L-type voltage-gated channel function is altered with CAD severity 
 To further and more specifically assess VGCC function, Ba2+-containing 
depolarizing solution with low Na+ was employed. Ca2+ influx through VGCC immediately 
triggers activation of Ca2+ extrusion and buffering mechanisms, which makes direct 
assessment of VGCC activity difficult. Fura-2 binds Ba2+ with similar affinity as to Ca2+. 
Substitution of Ca2+ with Ba2+ allows Ba2+ entry through VGCC upon depolarization. Ba2+ 
is not buffered by SERCA or transported by the plasma membrane Ca2+ ATPase. Low 
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extracellular Na+ inhibits Na+/Ca2+ exchange, preventing Ba2+ extrusion by this pathway, 
thereby providing a pure measure of VGCC function. For a representative tracing and 
experimental protocol, see Fig. 2.4F. 
 The rate of Ba2+ entry was assessed as the slope of the rise in the F340/F380 signal 
following depolarization. Rate of Ba2+ entry through VGCCs was dramatically increased 
in CSM from swine with mild CAD compared to Healthy and severe CAD (Fig. 2.4G). We 
also examined rate of Ba2+ entry following depolarization in the arterial wall (media) 
adjacent to the excised intima (plaque). VGCC activity was not different in CSM from 
plaques compared to CSM in their adjacent arterial media (Fig. 2.4H). The Healthy, Mild 
CAD, and Severe CAD histology with schematic illustrations of normal SR, increased 
SR, and decreased SR Ca2+ stores, respectively, are shown in Fig. 2.4I. The figure 
shows the proposed changes in Ca2+ handling associated with CSM phenotypic 
modulation during CAD progression.  
Cell proliferation declines with CAD severity 
To determine whether proliferation follows Ca2+ handling patterns, Ki-67 
expression was measured as an index of proliferative activity within coronary artery 
sections (Fig. 2.5A-D). The number of proliferative cells within the intimal region of 
coronary arteries with severe CAD was dramatically reduced, compared to arteries with 
mild CAD (Fig. 2.5E). 
Discussion 
There is a paucity of literature on a time course analysis of the connection 
between MetS-induced CAD and CSM Ca2+ regulation. This study steps into the gap and 
provides insight into the transitory, biphasic nature of CSM Ca2+ regulation during the 
progression of CAD. Using in vivo intravascular ultrasound imaging we showed 
increased circumferential neointimal wall coverage in early CAD and more severe 
increased plaque burden in late CAD. The power of IVUS is that after the highly 
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sensitive analysis of CAD progression the arteries are viable for interrogation of cellular 
Ca2+ signaling. We found increased Ca2+ influx and Ca2+ release and buffering by the 
sarcoplasmic reticulum in early CAD and a surprising reversal of these Ca2+ signaling 
events in more severe, late state CAD. By separating overt plaques away from medial 
CSM in the artery wall, we provide novel insight into heterogeneity of intracellular Ca2+ 
regulation in the different regions of severely diseased arteries. 
This clarity is important because there has been confusion regarding differences 
in intracellular Ca2+ regulation observed in several studies of CAD. For instance, Witczak 
et al. (79) and Hill et al. (81) reported increases in SERCA expression and function. 
Witczak et al. and others (80) also demonstrated decreases in VGCC function with 
disease. However, Neeb et al. (82) demonstrated a decrease in SERCA function with 
disease, and several studies (76-78) reported an increase in VGCC function with 
disease. One possible explanation for the apparent discrepancy in the data is duration of 
diet and/or severity of disease. Indeed, diet duration is different in each of these studies, 
causing differences in disease severity. An additional factor in these discrepancies may 
be the swine model. Witczak (79) and Hill (81) utilized diabetic dyslipidemic Yucatan 
swine that had no primary insulin resistance, while Berwick (76) utilized MetS Ossabaw 
swine with primary insulin resistance, hypertension, and increased aldosterone as major 
characteristics. Neeb (82) used both Ossabaw and Yucatan swine. Indeed, Neeb’s work 
highlights model differences in SERCA function (82), underscoring the need for time-
dependent studies in the same model. Specific components of the Ossabaw swine 
model that may contribute to differences in Ca2+ regulation include primary insulin 
resistance and increased aldosterone (186). The current study provides a repeat cross-
sectional examination of intracellular Ca2+ regulation in MetS Ossabaw swine during 
CAD progression, reconciling the discrepant results in the reports mentioned above. 
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Here, we report that function of VGCC and SERCA is enhanced with early, mild 
CAD and that these functions decrease with increased CAD severity. These data 
explain, in part, the discrepancies in the reports mentioned above. During early, MetS-
induced CAD, VGCC activity is increased, as observed by Berwick et al. (76) At the 
same time, SERCA activity is increased, as observed by Witczak et al (79). As MetS and 
CAD progress, however, VGCC and SERCA function are greatly diminished, which 
corresponds to the findings of Witczak (79) and Neeb (82). This decrease in VGCC and 
SERCA function appears to occur concurrently with a reduction in cell proliferation, as 
measured by Ki-67 expression. Future studies will seek to determine whether these 
phenomena are causally linked.  
Interestingly, in the repeat cross-sectional study, plasma triglycerides and total 
cholesterol were decreased after 12 months on atherogenic diet vs. 6 and 9 months, 
suggesting that plasma cholesterol could play a role in Ca2+ handling differences 
observed over CAD progression. This is unlikely, however, because the plasma 
cholesterol at 12 months was still increased ~4-fold above that in healthy lean pigs. 
Further, in the eleven month subset of swine used for analysis of Ca2+ handling in 
atherosclerotic plaque vs. media, total plasma cholesterol was not different in the mild 
vs. severe CAD groups, yet the decreases in SERCA and VGCC function persisted. 
These data suggest that the plasma cholesterol decrease in the repeat cross-sectional 
study did not explain the decrease in CSM Ca2+ handling in late CAD.  
 Additionally, this study provides new insight on intracellular Ca2+ regulation 
within atherosclerotic plaque. In the repeat cross-sectional study, CSM isolated from 
coronary arteries with “late” CAD were a mixed population of cells from the arterial wall 
and cells from the plaque. Here, for the first time isolating atherosclerotic plaques away 
from the artery wall, we provided a close-up look at CSM Ca2+ regulation within a plaque. 
Fig. 2.4D, E, and H provide strong evidence that SR Ca2+ handling is decreased in the 
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intima (plaques) of arteries with severe CAD, compared to its adjacent wall (media). This 
finding prompts several questions: 1) Does a shift in Ca2+ regulation within 
atherosclerotic plaques signal a shift in the dominant cell phenotype within an 
atherosclerotic plaque? 2) If so, can intracellular Ca2+ handling provide insight regarding 
plaque stability and phenotypic modulation? These questions are beyond the scope of 
the current project, but are interesting areas of future investigation. 
Together, the data in this report provide a much needed study of CAD 
progression in metabolic syndrome, providing insight on IVUS determinants of CAD 
severity and histological analysis of cellular components of CAD progression. The study 
also highlights the need for additional studies to further solidify causal links between 
intracellular Ca2+ regulation, CSM proliferation, and alterations in atherosclerotic plaque 
morphology during CAD progression.  
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Figures 
 
Figure 2.1: Intravascular ultrasound imaging of coronary arteries with varying 
stages of coronary artery disease in the repeat cross-sectional study. A. Cross-
sectional view of a coronary artery from a lean pig. B. Cross-sectional view of a coronary 
artery from a MetS pig with “early stage” CAD. Internal elastic lamina = yellow dotted 
line; lumen = red dashed line. C. Cross-sectional view of a coronary artery from a MetS 
pig with “late stage” CAD. Distance between blue dots in A-C is 1 mm. D. Wall coverage 
significantly increases in “early stage” CAD (0-9 months). Plaque burden does not 
increase until “late stage” CAD (>9 months). (lean= 4 pigs, MetS 6 months= 5 pigs, MetS 
9 months= 5 pigs, MetS 12 months= 7 pigs). E. Right anterior oblique coronary 
angiogram indicating lumen stenosis (arrow) in the left anterior descending artery. F. 
IVUS still frame which corresponds to lumen stenosis in panel E.  
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Figure 2.2: Intracellular Ca2+ signaling is biphasically altered in coronary smooth 
muscle cells during CAD progression in the repeat cross-sectional study. A. 
Representative tracing of CSM cytosolic Ca2+ flux. Labels indicate solution changes 
through superfusion chamber with duration shown by the horizontal lines. VGCC = 
voltage-gated Ca2+ channel; Caf = caffeine; green area under the curve = Ca2+ after 80 
mM K+ membrane depolarization; blue double-headed arrow = SR Ca2+ store release; 
red double-headed arrow = delayed recovery to basal Ca2+ levels due to impaired Ca2+ 
buffering and store-operated influx. B. 9 month duration of diet results in elevated Ca2+ 
influx following depolarization, compared to 6 and 12 months (dashed lines indicating 
significant differences) and to age-matched lean pigs (solid lines indicating significant 
differences). C. Tension development to KCl (20 mM) in isolated coronary rings 
paralleled the changes in K depolarization-induced Ca2+ in panel B. D. SR Ca2+ store 
release is elevated at 9 months on atherogenic diet, compared to 6 and 12 months 
(dashed lines indicating significant differences), and to age-matched lean pigs. E. 9 
months of atherogenic diet results in an increase in sustained Ca2+ signal, compared to 6 
and 12 months, but not to age-matched leans. (Lean = 9 pigs, cells = 60; MetS 6 months 
= 6 pigs, cells = 56; MetS 9 months = 7 pigs, cells = 68; MetS 12 months = 9 pigs, cells 
= 92). 
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Figure 2.3: Histological assessment of mild and severe CAD and collagen 
deposition. A-C Verhoeff-Van Gieson staining of elastin in a coronary arterial ring in 
lean (A), mild CAD (IVUS-detected plaque burden < 30%) (B), and severe CAD (IVUS-
detected plaque burden > 30%) (C). L = Lumen; M = Media (Wall). I = Intima (plaque). 
Black arrows indicate the internal elastic lamina adjacent to early atherosclerotic lesion. 
D – F. Picrosirius red staining of collagen deposition in lean (D), mild CAD (E), and 
severe CAD (F) coronary arterial rings. G. % plaque burden is increased with severe 
CAD. H. Intima/media ratio is increased with severe CAD. I. Intimal collagen deposition 
is increased in severe CAD. J. Medial collagen deposition demonstrates a trend (p = 
0.08) toward increase in severe CAD. (Mild CAD = 9 pigs; Severe CAD = 5 pigs) 
*p<0.05. 
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Figure 2.4: Intracellular Ca2+ handling is biphasically altered with CAD severity. A. 
Experimental protocol for panels B-E. B. The caffeine-sensitive steady-state SR store is 
increased in mild CAD compared to both healthy lean and severe CAD. C. The 
undershoot of cytosolic Ca2+ during recovery following removal of caffeine (SERCA 
activity) is increased in mild CAD compared to both healthy lean and severe CAD. D. 
When compared with CSM isolated from the adjacent arterial media (wall), intimal 
(plaque) CSM display decreased caffeine-releasable steady-state SR Ca2+ store. E. 
When compared with CSM isolated from the adjacent arterial media (wall), intimal 
(plaque) CSM display decreased SERCA activity. (Healthy = 6 pigs, cells = 67; Mild CAD 
= 9 pigs, cells = 156; Plaque = 5 pigs, cells = 29; Wall = 5 pigs, cells = 27). F. 
Experimental protocol for panels G-H. G. Rate of Ba2+ influx following depolarization is 
increased in CSM from mild CAD vs. Healthy and Severe CAD. H. When compared to 
CSM from the media (wall) adjacent to the plaque, intimal (plaque) cells do not 
demonstrate a difference in Ba2+ influx. (Healthy = 6 pigs, cells = 72; Mild CAD = 9 pigs, 
cells = 151; Plaque = 5 pigs, cells = 25; Wall = 5 pigs, cells = 42). I. Schematic depicting 
proposed changes in Ca2+ handling associated with CSM phenotypic modulation during 
CAD progression. Blue circles = Ca2+.  
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Figure 2.5: Cellular proliferation is decreased in severe CAD. A. Arterial ring from 
swine with mild CAD, interrogated with an antibody against Ki-67. B. Arterial ring from 
swine with severe CAD, interrogated with an antibody against Ki-67. C-D. Zoomed-in 
regions of rings in panels A and B. Black arrows indicate positive Ki-67 staining. 
Diamond arrows indicate negative Ki-67 stain. E. Ki-67 expression is decreased in 
severe CAD. (Mild CAD = 8 pigs; Severe CAD = 5 pigs).  
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Data-in-Brief 
Metabolic characteristics observed during a repeat cross sectional study of coronary 
artery disease progression in Ossabaw miniature swine 
(Published in Data in Brief 7:1393-1395, 2016 
doi:10.1016/j.dib.2016.04.023) 
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Abstract 
This repeat cross sectional study examined metabolic characteristics in Ossabaw 
miniature swine at different time points during atherogenic diet feeding. Briefly, metabolic 
syndrome was induced in Ossabaw miniature swine by feeding of an excess calorie, 
atherogenic diet for 6, 9, or 12 months. Ossabaw swine developed metabolic syndrome 
as indicated by increased body weight, hypertension, and increased plasma cholesterol 
and triglycerides, compared to lean controls. For more detailed explanations, see our 
associated research study (187). 
Specifications Table  
Subject area Physiology 
More specific subject 
area 
Metabolic syndrome development 
Type of data Table 
How data was acquired Plasma biochemical analysis 
Data format Analyzed 
Experimental factors Metabolic syndrome was induced by atherogenic diet 
feeding for 6, 9, and 12 months. 
Experimental features Repeat cross sectional study of metabolic syndrome 
induction at different time points of atherogenic diet feeding. 
Data source location Indianapolis, IN, United States of America. 
Data accessibility With this article 
 
Value of the data  
• These data could assist researchers in study design for induction of metabolic 
syndrome. 
• Provide previously unreported time-dependent aspects of metabolic syndrome. 
• May provide insight toward development of therapies at different time points of 
metabolic syndrome progression. 
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Data 
Metabolic syndrome has previously been defined as the presence of three or more of 
these risk factors: Obesity, hypertension, dyslipidemia (both LDL/HDL and triglyceride), 
insulin resistance, and glucose intolerance (169), and has been shown to double risk of 
developing coronary artery disease (15). Here, we conducted a repeat cross sectional 
analysis of metabolic syndrome development in Ossabaw swine during atherogenic diet 
feeding for 6, 9, and 12 months. Ossabaw swine developed metabolic syndrome, as 
indicated by increased body weight, hypertension, and dyslipidemia, compared to lean 
controls (Table 2.DiB.1). 
Table 2.DiB.1: Metabolic characteristics of Ossabaw miniature swine groups 
  Lean 
MetS 
(6 
months) 
MetS 
(9 
months) 
MetS 
(12 
months) 
Significance 
Body weight 
(kg) 62 ± 5 89 ± 2 87 ± 7 116 ± 2 12 > 9, 6 > lean 
Fasting Blood 
Glucose (mg/dL) 84 ± 6 75 ± 2 82 ± 7 81 ± 2 NS 
Systolic Blood 
Pressure 
(mmHg) 
131 ± 7 150 ± 9 143 ± 4 170 ± 7 12, 9, 6 > lean 
Diastolic Blood 
Pressure 
(mmHg) 
63 ± 2 77 ± 5 85 ± 4 89 ± 5 12, 9 > 6, lean 
Total 
Cholesterol 
(mg/dL) 
57 ± 5 383 ± 39 546 ± 66 247 ± 17 9 > 12, 6 > lean 
Triglycerides 
(mg/dL) 25 ± 4 34 ± 4 98 ± 34 43 ± 6 9 > 12, 6, lean 
NS = not significant. 
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Experimental Design, Materials and Methods 
Animal Care 
All experimental procedures involving animals were approved by the Institutional Animal 
Care and Use Committee at Indiana University School of Medicine with the 
recommendations outlined by the National Research Council and the American 
Veterinary Medical Association Panel on Euthanasia (182; 183). Six month old Ossabaw 
miniature swine were fed 1 kg of an excess-calorie atherogenic diet (KT-324, Purina 
Test Diet, Richmond, IN; 16% kcal from protein, 41% kcal from complex carbohydrates, 
19% kcal from fructose, and 43% kcal from fat). The feed was supplemented with 
cholesterol (2.0%), hydrogenated coconut oil (4.70%), hydrogenated soybean oil 
(8.40%), cholate (0.70%), and high fructose corn syrup (5.0%) by weight (82; 126; 134; 
148; 181)) daily for 6 (n=6), 9 (n=7), or 12 (n=9) months. Lean control swine (n=9) were 
fed 725 g of a standard diet (5L80, Purina Test Diet, Richmond, IN; 18% kcal from 
protein, 71% kcal from complex carbohydrates, and 11% kcal from fat). Swine were 
housed individually with free access to drinking water and on a 12-hour light/dark cycle. 
Metabolic Phenotyping 
Final body weights and blood were obtained at time of sacrifice. Plasma was obtained 
from heparinized whole blood by centrifugation at 2000 RPM for 20 minutes. Lipid and 
glucose biochemistry was performed by ANTECH Diagnostics (Fishers, IN). 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). One-way 
analysis of variance (ANOVA) with Bonferroni post hoc analysis was performed. Data 
are represented as mean ± SEM. p<0.05 was considered significant. 
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CHAPTER 3: SERCA ACTIVATOR CDN1163 INDUCES CORONARY SMOOTH 
MUSCLE PROLIFERATION IN AN ORGAN CULTURE MODEL OF CORONARY 
ARTERY DISEASE 
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Abstract 
Coronary artery disease (CAD) is characterized in part by de-differentiation and 
proliferation of coronary smooth muscle cells (CSM). Elevated sarcoplasmic reticulum 
(SR) Ca2+ stores and sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) function are 
increased in proliferating cells. Although elevated SERCA function is tightly associated 
with early CAD, a direct causal role has not been shown. The current study used the 
specific SERCA activator, CDN1163, to determine whether direct SERCA activation 
causes CSM proliferation in an organ culture model of medial thickening and cell 
proliferation. Coronary arterial rings were cultured for seven days in the presence and 
absence of the SERCA inhibitor, cyclopiazonic acid, then stained with Verhoeff Van-
Gieson’s elastin stain for assessment of medial thickening and with Masson’s trichrome 
for assessment of collagen deposition. Cell proliferation was assessed in the presence 
and absence of CDN1163 following serum starvation. Positive Ki-67 staining was used 
as an index of cell proliferation. Cyclopiazonic acid (CPA) prevented recovery of 
cytosolic Ca2+ to below baseline following depletion of the SR Ca2+ store, verifying the 
use of these cytosolic Ca2+ flux parameters as measures of SERCA activity. CPA 
treatment prevented culture-induced medial thickening, but not collagen deposition, 
during seven days of culture. CDN1163 induced cell proliferation in coronary arterial 
segments. Selective SERCA stimulation by CDN1163 increased CSM proliferation, while 
inhibition of SERCA activity by CPA prevented culture-induced medial thickening. Taken 
together, these results provide a much needed causal link between SERCA activation 
and CSM proliferation, providing a potential target for prevention of CAD. 
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Background 
  The coronary circulation is responsible for the delivery of oxygen and other 
crucial substrates to the myocardium. The tireless functioning of the heart is the impetus 
for high resting myocardial oxygen consumption, which requires efficient, unhindered 
oxygen delivery. Impediments to coronary blood flow result in long-lasting, drastic 
consequences, often as severe as myocardial infarction and death. 
Coronary artery disease (CAD) is often referred to as a “silent killer.” Because of 
the heart’s remarkable autoregulatory capacity, adequate myocardial blood flow can be 
maintained until restrictions in arterial lumen diameter exceed ~75-80% of the original 
lumen diameter (188). This means that CAD often progresses undetected for many 
years. Indeed, many studies have confirmed early atherosclerotic CAD in the conduit 
arteries of children and young adults (189-194), although it does not often clinically 
manifest until middle age (194). The silent nature of the disease necessitates greater 
understanding of early CAD, early detection, prevention, and/or treatment. 
One of the hallmarks of CAD progression is coronary smooth muscle (CSM) 
phenotypic modulation. In health, CSM cells are predominantly quiescent and 
contractile, exhibiting extremely low proliferative capacity. However, during early CAD 
and via mechanisms that are not fully defined, CSM cells are triggered to de-
differentiate, proliferate, and migrate toward the forming plaque (170), where they 
secrete extracellular matrix proteins such as collagen and elastin, thereby assisting in 
formation of a stabilized “cap” for the growing plaque (170).  
Intracellular Ca2+ handling mechanisms have often been implicated in induction 
of CSM cell proliferation. Indeed, elevated cytosolic Ca2+ is necessary for induction of 
cell cycle gene transcription via the nuclear factor of activated T-lymphocytes (NFAT) 
signaling pathway (72; 195). These elevations in cytosolic Ca2+ may be mediated either 
through Ca2+ influx or through Ca2+ release from internal Ca2+ stores (196-198). Indeed, 
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several pivotal studies conducted in the DDT1 MF-2 smooth muscle cell line by Gill’s 
group in the early 1990’s demonstrated that sarcoplasmic reticulum (SR) Ca2+ content is 
directly related to smooth muscle cell growth and proliferation (66-68). The sarco-
endoplasmic reticulum Ca2+ ATPase (SERCA) serves as the sole means by which the 
SR is populated with Ca2+, and Waldron et al (68) demonstrated that intact SERCA 
function is necessary for serum-induced smooth muscle cell proliferation. Indeed, 
SERCA expression is increased in pig aorta smooth muscle cell monolayer subcultures 
during platelet-derived growth factor (PDGF)-induced smooth muscle cell proliferation 
(199), specifically immediately prior to entrance into the S phase of the cell cycle (196). 
Our lab has demonstrated upregulation of SERCA function and expression in 
early CAD (79; 81; 82; 168), during peak proliferation within atherosclerotic plaques 
(187), but in the absence of specific SERCA activators, a causal link between SERCA 
activation and CSM proliferation has been elusive. Recently, CDN1163 has been 
identified as a specific activator of SERCA (200). The current study employed both 
SERCA activation and inhibition in an organ culture model of medial thickening and CSM 
proliferation (201-203) to test the hypothesis that increased SERCA function induces 
CSM de-differentiation and proliferation, thereby driving medial thickening. 
Methods 
Fluorescence imaging for assessment of cyclopiazonic acid action on sarco-
endoplasmic reticulum Ca2+-ATPase function 
CSM cells were enzymatically isolated from freshly dissected conduit coronary 
arteries and loaded with fura-2/AM (2.5 mmol/l Molecular Probes, Life Technologies, 
Eugene, OR) as previously described (79; 82; 126; 184). Fura-2 loaded cells were 
placed in physiologic salt solution composed of the following (in mM): 2CaCl2, 138 NaCl, 
1 MgCl2, 5 KCl, 10 HEPES, 10 glucose; pH 7.4) containing 0.02% bovine serum albumin 
and were kept on ice until experiments were performed. 20-25 µl fura-2 loaded CSM cell 
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suspension was placed on a coverslip contained in a constant-flow superfusion chamber 
mounted on an inverted epifluorescence microscope (model TMS-F, Nikon, Melville, 
NY), with flow maintained at 1-2 ml/min. Whole cell intracellular Ca2+ levels were 
expressed as the 360 nm (F360)/380 nm (F380) excitation ratio of the 510 nm fura-2 
emission at room temperature (22-25°C), using the InCa++ Imaging System Intracellular 
Imaging, Cincinnati, OH). Sarcoplasmic reticulum (SR) Ca2+ stores were released with 5 
mM caffeine in Ca2+-free solution (138 NaCl, 1 MgCl2, 5 KCl, 10 HEPES, 10-5 M K+-
EGTA, 10 glucose; pH 7.4) in the presence and absence of cyclopiazonic acid (CPA; 10 
µM; Santa Cruz Biotechnology, Dallas, TX). SERCA activity was assessed in the 
absence of extracellular Ca2+ as recovery of the F360/F380 signal relative to baseline 
following removal of caffeine. 
Organ culture of epicardial conduit coronary arteries 
 Epicardial coronary arteries were excised under sterile conditions from domestic 
swine hearts similar to previous reports (201-203). Arteries were cleared of adherent 
connective tissue and sectioned into arterial rings of 2-4 mm in length. Rings were 
cultured for seven days in 12-well plates at 37°C with 4.6% CO2 in a base media of 
Dulbecco’s modified eagle medium (DMEM; Sigma-Aldrich, St. Louis, MO) containing 
high glucose (180mg/dL), 1% penicillin streptomycin (PS; Gemini Bio-products, 
Sacramento, CA) and 20% fetal bovine serum (Gibco, Grand Island, NY). CPA (10 µM) 
was delivered to the culture medium using dimethyl sulfoxide (DMSO) as a vehicle. 
Another group was cultured in base media with DMSO as a negative control. Culture 
media was changed every two days. Cultured arterial rings were compared to freshly 
isolated coronary arteries as a control. 
Proliferation assay 
 Epicardial conduit coronary arteries were prepared as described above and 
cultured in 12-well plates at 37°C with 4.6 CO2 for three days in DMEM containing 
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normal glucose (100 mg/dL) and 1% PS in the absence of FBS (serum starved 
conditions). Then, fresh media was added and the culture was maintained for one day in 
the presence of the selective SERCA activator CDN1163 (10 µM; Neurodon, LLC) and in 
the presence or absence of CPA (10 µM). Control rings were cultured for the final day in 
serum free conditions without CDN1163 or CPA.  
Histology 
Coronary artery segments (2-4 mm in length) were placed in 10% phosphate-
buffered formalin for 24-48 hours and then transferred to 70% ethanol. Histology was 
performed in the Department of Anatomy and Cell Biology at Indiana University School 
of Medicine (Indianapolis, IN). Verhoeff van-Gieson (VVG) elastin stain was employed 
for interrogation of medial thickening. Masson’s Trichrome (TC) stain was employed for 
interrogation of extracellular matrix deposition. Images were captured using a LEICA DM 
300 inverted microscope and analyzed with Adobe Photoshop CS6 (Adobe Systems, 
Inc. San Jose, CA). 
Immunohistochemistry 
Coronary artery segments embedded in paraffin (described above) were 
transported the Department of Pathology at Indiana University School of Medicine and 
were processed as previously described (139). Immunostaining was performed using Ki-
67 as a proliferation marker. Images were captured using a LEICA DM 300 inverted 
microscope and analyzed with ImageJ as described in the data supplement. 
Statistical Analysis 
 Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA). 
One-way analysis of variance (ANOVA) with student Newman-Keuls post hoc analysis 
was performed. Data are represented as mean ± SEM. p<0.05 was considered 
statistically significant. 
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Results 
Cyclopiazonic acid inhibits SERCA-mediated recovery of cytosolic Ca2+ following SR 
Ca2+ store depletion with caffeine. 
 To verify CPA as an inhibitor of SERCA function, we released the SR Ca2+ store 
with caffeine (5 mM Caf in Fig. 3.1A) in the absence of extracellular Ca2+ and in the 
presence or absence of CPA (representative tracings in Fig. 3.1A). Following removal of 
caffeine, we assessed recovery of cytosolic Ca2+ relative to baseline as an index of 
SERCA function, as previously described (204). CPA effectively abolished the Ca2+ 
undershoot, verifying its use as a specific inhibitor of SERCA activity (Fig. 3.1B). 
Cyclopiazonic acid inhibits culture-induced medial thickening. 
 Medial thickness was assessed in VVG stained arterial segments as a 
percentage of total external elastic laminar area in fresh (Day 0; Fig. 3.2A) arterial 
segments, and in segments cultured for seven days in the absence (Fig. 3.2C) and 
presence (Fig. 3.2D) of CPA. Culturing of arterial segments increased medial area and 
this increase was prevented with CPA treatment (Fig. 3.2B). 
Cyclopiazonic acid treatment does not alter culture-induced collagen deposition. 
 Collagen deposition was examined in TC stained arterial segments as a 
percentage of total medial area in fresh (Day 0; Fig. 3.3A) arterial segments and in 
segments cultured for seven days in the absence (Fig. 3.3C) or presence (Fig. 3.3D) of 
CPA. Collagen content (blue staining in Figs. 3.3A-C) was increased with culture, but 
was not altered with CPA treatment (Fig. 3.3B). 
CDN1163 stimulation of SERCA induces CSM proliferation. 
 Following serum starvation, coronary arterial rings were cultured in the absence 
(Control; Fig. 3.4A) or presence (Fig. 3.4B) of CDN1163, and in the presence of 
CDN1163 and CPA (Fig. 3.4C) and Ki-67 positive staining was examined as an index of 
58 
cell proliferation (black arrows in Figs. 3.4A-C). CDN1163 increased cell proliferation ~3-
fold and this effect was blocked by the SERCA inhibitor CPA (Fig. 3.4D). 
Discussion 
 The current study examined SERCA inhibition and activation in an organ culture 
model of medial thickening and cell proliferation. Specific and direct stimulation of 
SERCA activity with CDN1163 induced CSM proliferation, while inhibition of SERCA 
activity with CPA completely abolished culture-induced medial thickening. Taken 
together, these data suggest that the elevated SERCA activity observed in early CAD 
(79; 81; 82; 168) causes the induction of the quiescent-to-proliferative phenotypic switch 
of CSM during the beginning stages of atherosclerotic lesion formation. 
 An interesting contribution to the discussion of SERCA and CSM proliferation 
during CAD progression is a series of studies in which gene transfer of SERCA2a halted 
culture-induced intimal thickening and CSM proliferation (72; 205; 206). While these data 
are seemingly at odds with earlier findings that elevated SERCA expression and function 
are associated with increased smooth muscle proliferation (196; 199), a couple of key 
experimental differences may shed light on the apparent discrepancies. Firstly, human 
coronary arteries used by the group at Mt. Sinai are obtained from explanted human 
hearts (72; 205) obtained at transplant. However, 37-46% of explanted hearts have overt 
CAD (207). Additionally, data from Nissen’s group indicate that, in adults between 20-29 
years of age, an estimated 66% of individuals have asymptomatic CAD (193). Therefore, 
it is likely that the group at Mt. Sinai is taking samples at their peak proliferative rate and 
labeling them “normal.” The current study takes arteries with 0% intimal thickness as 
baseline, thereby eliminating any confounding factor from early CAD-induced CSM 
proliferation at baseline. 
 Recently, we found that voltage-gated Ca2+ channel function is also increased in 
early CAD (168; 187), and we previously demonstrated that store-operated Ca2+ entry is 
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elevated in early CAD (126). Interestingly, a recent study in myometrial smooth muscle 
demonstrated that elevated SERCA function and activity increase store-operated Ca2+ 
entry, thereby depolarizing the sarcolemma and activating L-type voltage-gated 
channels (208). Future studies should undertake determination of the effect of SERCA 
upregulation on other Ca2+ transporters in organ culture, and determine whether these 
additional perturbations in Ca2+ regulation contribute to CSM de-differentiation.  
 This study provides evidence of a causal link between SERCA upregulation and 
CSM proliferation in early, asymptomatic CAD. These data are valuable, as they provide 
a potential target for early treatment of CAD through modulation of SERCA activity. 
Additionally, these data provide a potential early step in the cascade of CSM Ca2+ 
handling perturbations in early CAD.  
Acknowledgements 
The authors would like to thank Dr. Jose Estrada (Indiana University School of Medicine) 
for generous sharing of coronary tissue. 
Conflict of Interest 
There are no conflicts of interest to disclose. 
  
60 
Figures 
 
Figure 3.1: Cyclopiazonic acid inhibits SERCA-mediated recovery of cytosolic Ca2+ 
following SR Ca2+ store depletion with caffeine. A) Representative tracings obtained 
from interrogation of fura-2 (2.5 µM)-loaded CSM in the presence and absence of 
cyclopiazonic acid (CPA). B) CPA (White bar; 10 µM) prevents recovery of cytoplasmic 
Ca2+ to baseline levels. *, p<0.05. 
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Figure 3.2: Cyclopiazonic acid inhibits culture-induced medial thickening. Verhoeff 
Van-Gieson’s elastin stain was used to identify external (solid black line in A) and 
internal (dashed black line in A) elastic lamina in order to assess medial area as a 
percentage of total area inside the external elastic lamina. A) Fresh arterial rings were 
used as a control (Day 0). L = lumen; M = media; A = adventitia. B) Medial thickening 
was observed after 7 days in the absence of CPA; however this thickening was 
prevented by CPA treatment. *, p < 0.05. C) Coronary arterial ring cultured for 7 days in 
the absence of CPA. D) Coronary arterial ring cultured for 7 days in the presence of 
CPA. 
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Figure 3.3: Cyclopiazonic acid treatment does not alter culture-induced collagen 
deposition. Masson’s trichrome stain was used to identify collagen deposition (blue in 
panels A, C, and D) in culture. A) Fresh arterial rings were used as control (Day 0). B) 
Collagen content was increased after 7 days of culture, and this was not altered with 
CPA treatment. *, p < 0.05. C) Coronary arterial ring cultured for 7 days in the absence 
of CPA. D) Coronary arterial ring cultured for 7 days in the presence of CPA. 
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Figure 3.4: CDN1163 stimulation of SERCA induces CSM proliferation. Ki-67 
immunostaining was utilized as an index of proliferative activity. Positively stained nuclei 
are indicated with black arrows in panels A and B. Coronary arterial rings were serum 
staved for 72 hours. Culture media was changed, and rings were cultured for an 
additional 24 hours in the absence of serum and in the absence (A) or presence (B) of 
the SERCA activator, CDN1163. C) CPA was added in conjunction to CDN1163 and 
cultured for 24 hours. D) CDN1163 induced a ~3-fold increase in proliferation that was 
abolished by CPA.  
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CHAPTER 4: METABOLIC SYNDROME ABOLISHES GLUCAGON-LIKE 
PEPTIDE-1 RECEPTOR AGONIST STIMULATION OF SERCA IN CORONARY 
SMOOTH MUSCLE 
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Abstract 
Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. 
Glucagon-like peptide-1 (GLP-1) receptor agonists induce weight loss, increase insulin 
secretion, and improve glucose tolerance. Studies in healthy animals suggest 
cardioprotective properties of GLP-1 receptor agonists, perhaps partially mediated by 
improved sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) activity. We examined 
the acute effect of GLP-1 receptor agonists on coronary smooth muscle cells (CSM) 
enzymatically isolated from lean, healthy Ossabaw miniature swine. Intracellular Ca2+ 
handling was interrogated with fura-2. The GLP-1 receptor agonist, exenatide, activated 
SERCA, but did not alter other Ca2+ transporters. Further, we tested the hypothesis that 
chronic, in vivo treatment with GLP-1 receptor agonist, AC3174, would attenuate 
coronary artery disease (CAD) in swine with MetS. MetS was induced in 20 swine by six 
months feeding of a hypercaloric, atherogenic diet. Swine were then randomized 
(N=10/group) into placebo or AC3174 treatment groups and continued diet for an 
additional six months. AC3174 treatment attenuated weight gain, increased insulin 
secretion, and improved glucose tolerance. Intravascular ultrasound and histology 
showed no effect of AC3174 on CAD. MetS abolished SERCA activation by GLP-1 
receptor agonists. We conclude that MetS confers vascular resistance to GLP-1 receptor 
agonists, partially through impaired cellular signaling steps involving SERCA. 
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Background 
Metabolic syndrome (MetS) is defined as the presence of three or more of the 
following five risk factors: obesity, hypertension, glucose intolerance, insulin resistance, 
and dyslipidemia (169). Obesity, MetS, and type 2 diabetes are all independent risk 
factors for cardiovascular disease. The presence of MetS doubles risk of experiencing 
an adverse cardiovascular event (15). Thus, it is important to understand the effect of 
diabetes and MetS treatment modalities on cardiovascular health. 
Insulin-sensitizing drugs and those which enhance insulin secretion from 
pancreatic beta cells have been employed in the treatment of type 2 diabetes and MetS. 
Others, such as dipeptidyl peptidase-4 inhibitors, and glucagon-like peptide-1 receptor 
agonists (exenatide, liraglutide, AC3174, etc.) increase both insulin sensitivity and insulin 
secretion (33; 34). Recently, insulin-sensitizing thiazolidinediones have been implicated 
in increased risk of fluid retention, LDL and triglyceride accumulation, heart failure, and 
myocardial infarction (209-211). Hence, there is great attention on cardiovascular 
outcomes of anti-diabetic agents and the Food and Drug Administration requires 
cardiovascular safety profiles for all new agents (212).  
Glucagon-like peptide-1 (GLP-1) receptor agonists are attractive treatment 
options for MetS, because GLP-1 is an endogenous hormone which functions in normal 
physiology to increase insulin sensitivity, biosynthesis, and secretion (33). Additionally, 
GLP-1 receptor agonists reduce myocardial infarct size in ischemia/reperfusion injury 
(112), improve cardiac function in chronic heart failure (103), and attenuate neointimal 
formation following vascular injury (113). At the cellular level, GLP-1 receptor agonists 
improve endothelial calcium homeostasis following simulated ischemia/reperfusion 
(116). Further, GLP-1 receptor agonists improve sarco-endoplasmic reticulum Ca2+ 
ATPase (SERCA) activity in multiple cell types (114; 115). These studies provide 
rationale for a protective role of GLP-1 in the coronary vasculature. 
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A recent study revealed impaired GLP-1 stimulation of myocardial glucose 
uptake in human patients with type 2 diabetes and in MetS swine (91). This finding 
raises the question of potential resistance to GLP-1 in MetS and type 2 diabetes and 
highlights the need for rigorous examination of GLP-1 action on coronary artery disease 
(CAD), specifically in MetS. Given the stimulation of SERCA in macrophages and 
ventricular myocytes (114; 115) and altered SERCA in coronary smooth muscle (CSM) 
in MetS and diabetes (79; 82), potentially vaso-protective actions of GLP-1 could be 
mediated through cellular Ca2+ signaling. This study was investigated the effect of GLP-1 
receptor agonists on SERCA stimulation in CSM from lean swine and on coronary artery 
disease (CAD) and CSM SERCA stimulation in MetS. 
Methods 
Animals 
All protocols involving animals were approved by the institutional animal care and 
use committee at Indiana University School of Medicine, and fully complied with animal 
use standards (182; 183). Ossabaw miniature swine were separated into two treatment 
groups: placebo (N=10) and GLP-1 receptor agonist AC3174-treated (N=10; 0.25µg/kg 
body weight subcutaneously, twice daily; Amylin Pharmaceuticals, San Diego, CA), 
which displays nearly identical pharmacokinetic and pharmacodynamics profiles as the 
marketed GLP-1 receptor agonist, exenatide (34). CAD and MetS were induced in both 
treatment groups as described in the online supplement. One animal in the placebo 
group died prior to collection of endpoint data. 
Isolation of coronary smooth muscle cells 
Epicardial coronary arteries were cleaned of adherent tissue and CSM were 
isolated with a collagenase solution as described (79; 82) .  
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Measurement of intracellular Ca2+ 
CSM were loaded with fura-2/AM and whole cell intracellular Ca2+ levels were 
measured as described in the online supplement 
Acute in vitro exenatide treatment 
CSM from lean, healthy Ossabaw swine or a separate group of swine with MetS 
and CAD were treated with 100 nM exenatide during assessment of intracellular Ca2+. 
The selective SERCA inhibitor, cyclopiazonic acid (CPA, 10 µM) was utilized as a 
negative control for SERCA function. 
Intravenous glucose tolerance testing 
Intravenous glucose tolerance testing (IVGTT) was performed as described (82; 
148) and in the online supplement.  
Plasma Lipid, Electrolyte, and Enzyme Assays 
Blood samples were obtained at time of IVGTT prior to intravenous injection of 
glucose. Lipid electrolyte and enzyme content were measured offsite (Antech 
Diagnostics, West Lafayette, IN). 
Intravascular ultrasound 
After 12 months on diet, intravascular ultrasound pullbacks were performed as 
described in the online supplement.  
Histology 
Coronary arterial rings were placed in phosphate-buffered formalin at time of 
euthanasia. Hematoxylin & Eosin (H&E),  Verhoeff-van Gieson (VVG), and Trichrome 
(TC) staining were performed on sections of these rings. Plaque burden and collagen 
content were determined using commercially available software (ImageJ 1.48v, National 
Institutes of Health, USA) as described (82). 
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Results 
Acute in vitro exenatide treatment in CSM from lean, healthy swine 
We investigated the acute effect of the GLP-1 receptor agonist, exenatide, on 
intracellular Ca2+ handling in CSM isolated from lean, healthy Ossabaw swine. SR Ca2+ 
stores were released with caffeine in the absence of extracellular Ca2+ in the presence 
and absence of 100 nM exenatide (Fig. 4.1A), and the subsequent undershoot of 
cytosolic Ca during recovery was assessed. Exenatide treatment did not alter resting 
cytosolic Ca2+ (Fig. 4.1B) or Ca2+ influx through voltage-gated Ca2+ channels (Fig. 4.1C). 
Exenatide elicited improved recovery of cytosolic Ca2+ below baseline levels and this 
effect was completely ablated in the presence of the SERCA inhibitor CPA (Fig. 4.1D). 
The GLP-1 receptor agonist liraglutide also demonstrated improved recovery of cytosolic 
Ca2+, which was prevented by the GLP-1 receptor antagonist, exendin (9-39) (Fig. 4.S1). 
In the presence of caffeine, SERCA buffering of cytosolic Ca2+ is functionally inhibited, 
because of the much more rapid release of Ca2+ through ryanodine receptors on the SR 
membrane. Therefore, we assessed the rate of recovery to 50% recovery to baseline 
(T50), in the presence of caffeine as a measure of Ca2+ extrusion and/or Ca2+ uptake into 
caffeine-insensitive intracellular stores and to 100% recovery to baseline (T100) in the 
absence of caffeine as another measure of SERCA activation. Exenatide significantly 
decreased time to 100%, but not 50% recovery to baseline (Fig. 4.1E). 
Clinical measurement of MetS in Ossabaw swine 
We then investigated the chronic effect of GLP-1 receptor agonism in vivo. To 
examine the effects of diet and GLP-1 receptor treatment on glucose metabolism, kidney 
function, and plasma electrolytes, blood profiles of these parameters were obtained 
(Table 4.S1) and IVGTTs were performed. Overall, feeding of an excess calorie, 
atherogenic diet increased body weight, which was significantly attenuated by AC3174 
treatment (Fig. 4.2A). Blood pressure was not altered by diet or AC3174 treatment. 
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While fasting plasma glucose was not altered by diet or AC3174 treatment (Table 4.S1), 
IVGTT assessment of glucoregulation revealed improved glucose handling in AC3174 
treated swine, compared to placebo (Fig. 4.2B-D). This was corroborated by augmented 
plasma insulin levels following intravenous glucose challenge in AC3174 treated 
animals, compared to placebo (Fig. 4.2E-G).  
Intravascular ultrasound and histology measurement of CAD 
Intravascular ultrasound (IVUS) was employed to examine severity of CAD in 
vivo and was confirmed by histology. Both wall coverage and percent plaque burden 
were assessed as previously described (82) in placebo and AC3174-treated pigs. 
AC3174 treatment did not alter CAD severity as indicated by either wall coverage or 
percent plaque burden (Fig. 4.3C-D). In vitro, histological examination of coronary 
arterial rings revealed no effect of AC3174 treatment on plaque burden (Fig. 4.3E-F; I-J; 
H), collagen deposition (Fig. 4.3G; K-L). 
Effect of chronic, in vivo GLP-1 receptor agonist treatment on CSM Ca2+ handling in 
MetS-induced CAD. 
We have previously demonstrated alterations in coronary smooth muscle (CSM) 
Ca2+ handling in MetS-induced CAD (79; 82; 180) . We therefore investigated whether 
chronic, in vivo AC3174 treatment resulted in improved intracellular Ca2+ handling in 
CSM. Fig. 4.4A shows the Ca2+ signaling protocol to assess baseline Ca2+ levels, 
sarcoplasmic reticulum (SR) Ca2+ store release assessed by the caffeine-induced Ca2+ 
peak in the absence of extracellular Ca2+, and SERCA activity assessed by subsequent 
recovery of cytosolic Ca2+ levels and undershoot of cytosolic [Ca2+] below baseline 
levels. Chronic AC3174 treatment did not alter intracellular Ca2+ handling in CSM from 
swine with MetS-induced CAD (Fig. 4.4B-D).  
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Effect of acute, in vitro exenatide treatment on CSM in MetS and CAD 
Further, we assessed the acute, direct effect of GLP-1 receptor agonists on Ca2+ 
handling in CSM isolated from swine with MetS and CAD. Cells were exposed to the 
GLP-1 receptor agonist, exenatide (100 nM), which has an identical pharmacological 
profile as AC3174 (34) (Fig. 4.4A) for three minutes prior to treatment with high K+. We 
again assessed caffeine-induced SR Ca2+ store release by peak Ca2+ response to 
caffeine and SERCA activity by the subsequent undershoot of cytosolic Ca2+ during 
recovery. Exenatide did not alter either SR Ca2+ store release or the undershoot of 
cytosolic Ca2+ below baseline (Fig 4.4E-F). 
Discussion 
 The principle finding of this study is that MetS confers vascular resistance to the 
effects of GLP-1 receptor agonists. AC3174 did improve several cardiovascular risk 
factors, such as the metabolic factors, glucose tolerance and insulin secretion, indicating 
that longer term treatment may have indirect benefits on cardiovascular health. 
Treatment of MetS and type 2 diabetes is confounded by potential secondary and 
detrimental cardiovascular effects. Previous studies in lean, healthy animals indicate that 
GLP-1 receptor agonists provide a potential cardioprotective treatment for type 2 
diabetes and MetS (103; 112; 113). In the current study, we examined possible Ca2+ 
regulatory mechanisms for GLP-1 receptor agonist action in CSM from lean, healthy 
Ossabaw swine. Our finding that GLP-1 receptor agonists exert a positive effect on 
SERCA activity in coronary smooth muscle from lean Ossabaw swine is in agreement 
with findings that GLP-1 receptor agonists enhance SERCA activity in other cell types, 
including endothelial cells (116), macrophages (114), and cardiomyocytes (115), and is 
the first study examining the effect of GLP-1 receptor agonists in CSM. The kinetics of 
the Ca2+ transient shown in Fig. 4.1E demonstrate a lack of exenatide effect on Ca2+ 
extrusion. We have previously shown these kinetic measurements to be an appropriate 
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assay of Ca2+ extrusion (79). Reduced SERCA activity has been implicated in CSM 
proliferation and neointimal formation in the progression of CAD (73; 206). One possible 
mechanism explaining this phenomenon is induction of endoplasmic reticulum (ER) 
stress. As the single means by which Ca2+ may enter the ER, SERCA is a crucial 
regulator of ER Ca2+ homeostasis, and SERCA inhibition elicits an ER stress response 
through depletion of ER Ca2+(213). ER stress is associated with development of 
atherosclerosis (114). Inhibition of ER stress through heightened activation of SERCA 
could provide a novel means by which to treat CAD. 
We also examined the effect of GLP-1 receptor agonists on CAD progression in 
MetS. This study was needed because of recent evidence of MetS-induced resistance to 
the cardioprotective effects of GLP-1 (91). The improvement of systemic glucoregulation 
with AC3174 treatment provides essential positive evidence for GLP-1 receptor agonist 
action in the Ossabaw swine model of MetS and CAD. Further, we demonstrated that 
GLP-1 receptor agonist, AC3174 has no effect on MetS-induced CAD. This is in contrast 
with the recent finding that GLP-1 prevents myocardial ischemia-reperfusion injury (112) 
and injury-induced neointimal hyperplasia (113), providing evidence that the MetS 
phenotype itself confers cardiovascular resistance to the beneficial effects of GLP-1. It is 
important to note that, while AC3174 treatment did not attenuate CAD progression, the 
absence of adverse effects of AC3174 provide a cardiovascular safety profile for GLP-1 
receptor agonists. 
Additionally, we examined the acute, direct effect of GLP-1 receptor agonists on 
intracellular Ca2+ regulation in CSM from Ossabaw swine with MetS and CAD who had 
not received any treatment with GLP-1 receptor agonists. Here, we found that exenatide 
had no effect on Ca2+ regulation in CSM from swine with MetS and CAD. This finding is 
in contrast with other studies in which GLP-1 receptor agonism resulted in increased 
SERCA activity (114-116). A study in humans with type 2 diabetes revealed that 
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exenatide treatment enhanced endothelial-dependent vasodilation (214), although it is 
important to note that blood cholesterol levels were controlled in these patients. The 
current study, revealing a lack of effect of GLP-1 receptor agonism on SERCA activity in 
the setting of MetS corroborates the earlier finding that MetS ablated the effect of GLP-1 
receptor agonists in myocardium and highlights the need for additional studies to 
investigate specific aspects of MetS (obesity, hyperinsulinemia, glucose intolerance, 
hypertension, and dyslipidemia) that may underlie resistance of the coronary vasculature 
to GLP-1 receptor agonists. 
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Figures 
 
Figure 4.1: Effect of acute exenatide treatment on CSM Ca2+ handling in CSM 
isolated from lean, healthy Ossabaw swine. A) Representative tracing of data from 
Ca2+ imaging protocol. Horizontal dashed line indicates baseline. (Control n = 114 CSM; 
Exen n = 82 CSM; CPA n = 68 CSM) B) Resting cytosolic Ca2+. C) Area under the curve 
(AUC) for Ca2+ influx during high K+, corresponding to the shaded region in panel A. D) 
Undershoot of Ca2+ below resting levels, corresponding to the black vertical arrow in 
panel A. E) Time to half (t50) and total (t100) recovery from caffeine-induced rise in 
cytosolic Ca2+, corresponding to the horizontal black arrows in panel A. 
75 
 
Figure 4.2: AC3174 attenuates weight gain and improves glucose handling in 
Ossabaw miniature swine. Closed circles = placebo treatment group. Open circles = 
AC3174 treatment group. A) Weight gain in Ossabaw miniature swine. Inset timeline 
indicates time on placebo or AC3174 treatment, which corresponds with times in B-D 
and Table S1. B-D) Time course of plasma glucose responses during IVGTT at B) 
beginning, C) 12 weeks, and D) 24 weeks of AC3174 treatment. E-G) Time course of 
plasma insulin responses during IVGTT at E) beginning, F) 12 weeks, and G) 24 weeks 
of AC3174 treatment.  
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Figure 4.3: AC3174 treatment does not attenuate CAD progression as measured 
by intravascular ultrasound (IVUS) and histology. A) IVUS image of artery with CAD. 
Lumen traced in white dashed line. L = Lumen, C = Catheter. Distance between dots is 1 
mm. Lumen traced in white dotted line. Arterial wall traced in white dashed line. 
Atherosclerotic plaque is indicated between dotted and dashed lines. B) The heart and 
major epicardial coronary arteries. RC = right coronary artery, LAD = left anterior 
descending, CFX = circumflex. The RC and CFX on the anterior aspect of the heart are 
shown by the solid lines and the arteries traversing to the posterior aspect of the heart 
are shown by the dashed lines. The IVUS catheter is shown in the RC positioned for a 
pullback. C, D) Quantification of IVUS pullbacks performed in the RC in both placebo (n 
= 6) and AC3174-treated (n = 3) swine. AC3174 did not attenuate CAD as measured by 
percent plaque burden (panel C) or percent wall coverage (panel D). E-G; I-K: Coronary 
arterial rings from placebo (n = 4; panels E-G) and AC3174-treated (n = 5; panels I-K) 
swine. In panels F and J: A = Adventitia; I = Intima; L = Lumen; M = Media. A, E) 
Coronary artery rings stained with hematoxylin & eosin (H&E). F, J) Coronary artery 
rings stained with  Verhoeff-van Gieson (VVG) stain for elastin. An overt atherosclerotic 
plaque is traced in panel H. G, K) Coronary artery rings stained with Masson’s trichrome 
(TC) for collagen. H) Graphical representation of plaque burden, (p = 0.35) L) Graphical 
representation of total collagen area, (p = 0.79). 
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Figure 4.4: Effect of GLP-1R agonists on CSM Ca2+ handling in MetS Ossabaw 
swine. A) Representative tracing of data from Ca2+ imaging protocol. Dashed line 
indicates baseline. B-D) Effect of chronic in vivo AC3174 treatment on CSM Ca2+ 
handling. (Placebo n = 4 swine; AC3174 n = 6 swine) B) Resting cytosolic Ca2+ levels. 
C) Caffeine-induced SR Ca2+ store release. Corresponds to brackets in panel A. D) 
Undershoot of cytosolic Ca2+ levels below baseline. Corresponds to black arrow in panel 
A. E-F) Effect of acute ex vivo exenatide treatment on Ca2+ handling in CSM from MetS 
Ossabaw swine. (0Ca n = 38 CSM; Exen n = 24 CSM) E) Caffeine-induced SR Ca2+ 
store release. Corresponds to brackets in panel A. F) Undershoot of cytosolic Ca2+ levels 
below baseline. Corresponds to black arrow in panel. 
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Data Supplement 
Animals. 
Coronary artery disease (CAD) and metabolic syndrome (MetS) were induced in both 
treatment groups by feeding, once daily for 6 months, 1 kg of atherogenic diet, 
containing 16% kcal from protein, 41% kcal from complex carbohydrates, 19% kcal from 
fructose, and 43% kcal from fat, and supplemented with 2.0% cholesterol and 0.7% 
sodium cholate by weight (KT324, Purina Test Diet, Richmond, IN), as previously 
described (82; 126; 139). Following 6 months on this diet, swine were placed on placebo 
or AC3174 treatment twice daily and feeding was altered to 0.5 kg twice daily for an 
additional six months. Water was provided ad libitum. Six lean, age-matched Ossabaw 
miniature swine fed a standard chow diet (5L80, Purina Lab Diet, Richmond, IN) were a 
control group to verify presence of MetS. Coronary smooth muscle (CSM) cells were 
isolated from additional lean and MetS swine for acute, in vitro assessment of GLP-1 
receptor agonist action on intracellular Ca2+ handling (see acute in vitro exenatide 
treatment methods). 
Measurement of intracellular Ca2+ levels. 
CSM were loaded with the fluorescent intracellular Ca2+ indicator, fura-2/AM. Fura-2 
loaded cells were placed on a coverslip contained in a constant-flow superfusion 
chamber mounted on an inverted epifluorescence microscope (model TMS-F, Nikon, 
Melville, NY), with flow maintained at 1-2 ml/min. Whole cell intracellular Ca2+ levels 
were assessed as the 360 nm/380 nm excitation ratio of the fura-2 emission at 510 nm 
at room temperature (22-25 °C), using the InCa++ Ca2+ Imaging System (Intracellular 
Imaging, Cincinnati, OH) as previously described (63; 79; 82; 126; 160; 184; 201; 215; 
216). Basal Ca2+ levels were measured in physiologic salt solution (PSS) composed of 
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the following (in mM): 2 CaCl2, 138 NaCl, 1 MgCl2, 5 KCl, 10 HEPES, 10 glucose; pH 
7.4). Voltage-gated calcium channels were activated by depolarization with high (80 mM) 
K+ solution (2 CaCl2, 63 NaCl, 1 MgCl2, 80 KCl, 10 HEPES, 10 glucose; pH 7.4). 
Sarcoplasmic reticulum (SR) Ca2+ stores were released with 5 mM caffeine in Ca2+-free 
solution (138 NaCl, 1 MgCl2, 5 KCl, 10 HEPES, 10-5 M K+-EGTA, 10 glucose; pH 7.4). 
Intravenous glucose tolerance testing. 
Briefly, swine were pre-acclimated to sling-restraint. Following an overnight fast, swine 
were restrained in the low stress sling and baseline blood samples and tail-cuff blood 
pressures were obtained. Next, glucose (1 g/kg body weight) was administered 
intravenously as a bolus and timed blood samples were collected. Blood glucose was 
measured immediately (YSI 2300 STAT Plus Glucose analyzer, YSI Life Sciences, 
Yellow Springs, OH). Plasma insulin assays were performed offsite (Millipore, Inc., St 
Charles, MO). 
Intravascular ultrasound. 
After 12 months on diet, following an overnight fast, swine received 2.2 mg/kg xylazine 
and 5.5 mg/kg telazol, similar to previous reports (69; 82; 126; 139; 165; 184). Swine 
were intubated and anesthesia was maintained at 2-4% isoflurane in 100% O2 as a 
carrier gas. A 7 F introducer sheath was inserted into the right femoral artery and 
heparin (200 U/kg) was administered. A 7 F guiding catheter (Amplatz L, sizes 0.75-2.0; 
Corndis, Bridgewater, NJ) was advanced to engage either the right or left coronary 
ostium. A 3.2 F, 40 MHz IVUS catheter (Boston Scientific, Natick, MA) was advanced 
over a guide wire and positioned in the coronary artery. Automated IVUS pullbacks were 
performed at 0.5 mm/sec. Angiography was performed throughout the procedure to 
assist in catheter placement. 
80 
 
Figure 4.S1: Liraglutide increases SERCA activity in CSM from lean, healthy 
Ossabaw Swine, and this effect is prevented in the presence of GLP-1 receptor 
antagonist, Exendin (9-39). 
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Table 4.S1: Phenotypic Characteristics of Ossabaw Swine Groups. 
Parameter Lean Placebo AC3174 Significance, * (p < 0.05) 
Week on Treatment  0 12 24 0 12 24  
Body Weight 61 ± 6 75 ± 3 100 ± 2* 116 ± 2* 73 ± 4 87 ± 5 100 ± 6* Lean < AC3174 < Placebo 
Blood Pressure         
Systolic (mmHg) 143 ± 8 149 ± 8 151 ± 4 170 ± 7 132 ± 5 149 ± 6 152 ± 6 None 
Diastolic (mmHg) 76 ± 5 79 ± 5 84 ± 3 89 ± 5 74 ± 4 82 ± 5 85 ± 4 None 
Mean Arterial Pressure 
(mmHg) 98 ± 5 102 ± 5 106 ± 2 116 ± 5 93 ± 4 104 ± 5 107 ± 4 
None 
Carbohydrate 
Metabolism        
 
Fasting plasma glucose 
(mg/dL) 77 ± 5 74 ± 2 78 ± 2 81 ± 2 72 ± 3 73 ± 3 68 ± 2 
None 
Peak plasma insulin 
(µU/dL) 88 ± 33 47 ± 17 47 ± 6 67 ± 12 46 ± 10 139 ± 29* 122 ± 25* 
Placebo < AC3174 
Lipids         
Total cholesterol (mg/dL) 66 ± 10 430 ± 95 420 ± 68 240 ± 20 460 ± 78 369 ± 65 354 ± 61 Lean < Placebo, AC3174 
Triglycerides (mg/dL 29 ± 5 67 ± 16 46 ± 6 41 ± 4* 60 ± 6 64 ± 13 74 ± 7* Lean < Placebo < AC3174 
Kidney Function         
BUN (mg/dL) 13 ± 1.0 15 ± 1.4 13 ± 0.9 13 ± 1.2 16 ± 1.2 14 ± 1.4 15 ± 1.2 None 
Creatinine (mg/dL) 1.2 ± 0.09 1 ± 0.04 0.9 ± 0.05 1 ± 0.04 1.1 ± 0.09 1 ± 0.07 1 ± 0.04 None 
Plasma Proteins         
Total Protein (g/dL) 7.1 ± 0.2 6.2 ± 0.4 6.7 ± 0.2 6.8 ± 0.2 6.4 ± 0.4 6.8 ± 0.7 6.6 ± 0.2 None 
Albumin (g/dL) 4 ± 0.2 3.6 ± 0.1 3.6 ± 0.1 3.7 ± 0.2 3.7 ± 0.1 3.9 ± 0.1 3.8 ± 0.1 None 
Globulin (g/DL) 3.3 ± 0.2 2.9 ± 0.1 3.1 ± 0.2 3.1 ± 0.1 2.8 ± 0.2 2.9 ± 0.1 2.8 ± 0.1 None 
Electrolytes         
Phosphorus (mg/dL) 5.8 ± 0.2 7 ± 0.1* 6.7 ± 0.2 6.2 ± 0.2 6.7 ± 0.2* 6.1 ± 0.2* 6 ± 0.2 Lean < Placebo > AC3174 
Calcium (mg/dL) 10.3 ± 0.1 9.7 ± 0.2 9.4 ± 0.2 9.5 ± 0.3 9.7 ± 0.3 9.8 ± 0.3 9.5 ± 0.2 None 
Magnesium (mEq/L) 1.6 ± 0.1 1.8 ± 0.1 1.7 ± 0.1 1.6 ± 0.1 1.7 ± 0.1 1.7 ± 0.1 1.6 ± 0.1 None 
Sodium (mEq/L) 140 ± 1 140 ± 1 137 ± 2 139 ± 1 141 ± 1 137 ± 2 138 ± 2 None 
Potassium (mEq/L) 4.3 ± 0.3 4.2 ± 0.1 4.3 ± 0.1 4 ± 0.1 4.3 ± 0.1 4.2 ± 0.1 3.9 ± 0.1 None 
Chloride (mEq/L) 102 ± 1 99 ± 1 97 ± 1 106 ± 8 100 ± 1 97 ± 1 98 ± 1 None 
Other         
Creatine Phosphokinase 537 ± 225 422 ± 40 502 ± 56 448 ± 54 364 ± 54 410 ± 72 645 ± 321 None 
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CHAPTER 5: CONCLUSION 
Summary of Findings 
 The prevalence of metabolic syndrome (MetS) in the United States (US) 
continues to fuel cardiovascular disease, which takes more lives than any other cause 
(10; 15-17; 37; 45). In particular, coronary artery disease (CAD) is the underlying cause 
in 1 out of every 7 deaths in the US (6). Projections to 2030 predict that 40.5% of all US 
citizens will have some form of cardiovascular disease (38). This rise in cardiovascular 
disease continues to place an ever-increasing burden on healthcare systems in the US 
to develop innovative treatment strategies to combat this “silent killer” of Americans.  
 Coronary smooth muscle (CSM) physiology in the setting of CAD is an important 
area of current cardiovascular research, and is the focus of this dissertation. In 
particular, alterations in CSM phenotypes (termed phenotypic modulation) observed 
during CAD progression have elicited much attention. Recent efforts to organize 
understanding of developmental, mature, and pathologic CSM phenotypes have been 
the subject of critical reviews (54; 217; 218). These studies indicate that de-differentiated 
CSM display enhanced proliferative and secretory capabilities, assisting in formation of a 
fibrous cap during early CAD pathophysiology. Proliferative CSM may later differentiate 
into osteogenic CSM, depositing mineral crystals into the atherosclerotic lesion. 
Ultimately, CSM apoptosis may contribute to plaque rupture and myocardial infarction 
(219). Fig. 5.1 depicts these phenotypic changes during CAD progression, together with 
the intracellular Ca2+ handling changes described below. 
 Changes in intracellular Ca2+ regulation within CSM have been implicated in CAD 
pathogenesis, as Ca2+ is a ubiquitous second messenger and affects many cellular 
processes, including CSM contraction, proliferation, and apoptosis. Alterations in Ca2+ 
handling protein function contribute to disrupted cytosolic and compartmental Ca2+ 
concentrations, thus altering normal contractile function, as well as proliferation and 
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apoptosis pathways. In particular, increased sarcoplasmic reticulum (SR) Ca2+ is 
associated with proliferation in smooth muscle cell lines (66-68) and intact sarco-
endoplasmic reticulum Ca2+ ATPase (SERCA) function is necessary for CSM 
proliferation (68). Indeed, SERCA expression and function is increased during early CAD 
(79; 81; 82; 187). Increased CSM proliferation contributes to CAD progression through 
assistance with outward remodeling and plaque stabilization in early CAD.  
In light of these data, the primary objective of this work was to investigate 
SERCA function during MetS-induced CAD progression, elucidate a causal role for 
SERCA upregulation in CSM proliferation, and investigate the effects of secondary 
SERCA activation with glucagon-like peptide-1 receptor agonists on MetS-induced CAD 
progression in vivo. This was accomplished in three independent studies, outlined in the 
specific aims below. 
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Specific Aim 1: Examine the changes in CSM Ca2+ regulation during MetS-induced 
CAD progression. Specifically, examine changes in SR Ca2+ handling with 
increasing CAD severity. In this repeat cross-sectional study, we determined that 
alterations in CSM Ca2+ regulation during CAD progression are transitory and biphasic. 
During early and clinically insignificant CAD, Ca2+ handling by all of the transporters 
examined was significantly increased. This increased activity by Ca2+ transporters 
occurred concurrently with an observed increase in coronary vasoconstriction. Later in 
CAD, Ca2+ transporter function is dramatically reduced, together with reductions in 
vasoactivity. Specifically, CSM isolated from plaques of arteries with severe CAD 
demonstrated a reduced SR Ca2+ store, together with reductions in SERCA function, 
compared both to healthy and mild CAD samples. The reductions in SR Ca2+ store and 
SERCA function were mirrored by reductions in CSM proliferation in arteries with severe 
CAD, compared to those with mild CAD. These findings support the hypothesis that 
SERCA function is linked to CSM proliferation, and thereby, plaque formation during 
CAD progression. 
Specific Aim 2: Test the hypothesis that increased SERCA function induces CSM 
de-differentiation and proliferation in an organ culture model of CAD. The goal of 
this study was to establish a causal link between upregulation of SERCA function and 
induction of CSM proliferation in an organ culture model of CAD. Blockade of SERCA 
with the selective SERCA inhibitor, cyclopiazonic acid (CPA), prevented culture-induced 
medial thickening. Conversely, stimulation of SERCA with the selective SERCA 
activator, CDN1163 induced CSM proliferation, as assessed by positive Ki-67 staining. 
These findings are consistent with the hypothesis that the elevated SERCA function 
observed in early CAD is a proximal inducer of CSM proliferation. 
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Specific Aim 3: Investigate the effects of glucagon-like peptide-1 receptor 
agonists on SERCA stimulation in vitro in CSM from lean swine and on CAD and 
CSM SERCA stimulation in MetS in vivo. Here, we examined the effects of GLP-1 
receptor agonists both on intracellular Ca2+ regulation and on overall CAD progression. 
We demonstrated that acute treatment of CSM from healthy Ossabaw swine with GLP-1 
receptor agonists had a stimulatory effect on SERCA activity. Conversely, acute in vitro 
treatment of CSM from Ossabaw swine with MetS with GLP-1 receptor agonist, or its 
chronic administration in vivo had no effect on SERCA activity. Correspondingly, no 
alterations in CAD progression were observed with GLP-1 receptor agonist 
administration. However, we did demonstrate improvement of several metabolic 
parameters with GLP-1 treatment, including glucose regulation and body weight. These 
results support the hypothesis that MetS confers cardiovascular resistance to GLP-1 
receptor agonists, and suggest that this resistance is mediated, in part, through a lack of 
SERCA responsiveness to GLP-1 receptor activation.  
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Future Directions 
 There is a substantial body of evidence for altered CSM Ca2+ regulation in CAD 
(76-80; 82; 126; 160; 187). In this dissertation I have established a causal link between 
elevated SERCA function and CSM proliferation. However, a variety of questions remain 
unanswered regarding additional Ca2+ handling anomalies observed in CAD, as well as 
their effect on further phenotypic modulation during CAD progression. 
 Intracellular Ca2+ handling mechanisms in CSM were discussed in detail in 
chapter one (Fig. 1.6). Briefly, a number of Ca2+ transport proteins are employed to 
maintain optimal Ca2+ concentrations both in the cytosol and in intracellular Ca2+ 
compartments, such as the SR. These include two Ca2+ entry channels located on the 
sarcolemmal membrane: voltage-gated Ca2+ channels (VGCC) and transient receptor 
potential channels (TRP), two sarcolemma-bound extrusion mechanisms: the Na+/Ca2+ 
exchanger (NCX) and the plasma membrane Ca2+ ATPase (PMCA), two SR Ca2+ 
release channels: the ryanodine receptor (RyR) and the inositol 1,4,5-trisphosphate 
receptor (IP3R), and the sarco-endoplasmic reticulum Ca2+ ATPase (SERCA), which is 
responsible for maintaining optimal SR Ca2+ load. 
Direct or indirect interaction between Ca2+ handling proteins is necessary for 
maintenance of proper Ca2+ concentrations. We have taken advantage of these 
interactions to study a variety of Ca2+ handling events. Indeed, early experiments in our 
lab and others employed Ca2+ influx via VGCCs to load the SR with Ca2+ (184; 220-222) 
and observe subsequent “SR Ca2+ unloading” events (63-65; 222-225). A classic 
example of Ca2+ handling protein interaction is that of store-operated Ca2+ entry (SOCE), 
in which depletion of the SR Ca2+ store results in a signal to the sarcolemma, triggering 
Ca2+ influx either directly through store-operated Ca2+ channels or via reverse-mode 
NCX activity triggered by Na+ influx through TRP channels (126; 226-228). We have 
previously demonstrated that SOCE is mediated in Ossabaw swine via TRP canonical 1 
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(TRPC1) (126). Interestingly, an intact SOCE complex is necessary for CSM proliferation 
(72). I hypothesize that a cycle in which elevated SERCA activity results in SR Ca2+ 
unloading either via IP3R or RyR-mediated release (229), in turn triggering a 
compensatory rise in cytosolic Ca2+ via SOCE. SERCA function is then further 
upregulated to sequester additional cytosolic Ca2+, resulting in chronically elevated 
cytosolic and SR Ca2+, thereby initiating proliferative pathways. Fig. 5.2 illustrates this 
hypothetical scenario in which both SR Ca2+ and cytosolic Ca2+ levels are elevated and 
contribute to CSM proliferation. 
 CSM dedifferentiation to a proliferative phenotype during CAD is compensatory – 
in the media, CSM proliferation contributes to outward remodeling of the artery, thus 
maintaining adequate lumen diameter (43; 230; 231), while in the intima, proliferative 
CSM serve to stabilize the plaque and protect against plaque rupture (230; 232). Thus, 
the increased activity of SERCA and other Ca2+ transporters in CSM during the early 
stages of CAD may be protective. Later decreases in the activity of these Ca2+ 
transporters may signal further phenotypic modulation to osteogenic or apoptotic 
phenotypes, contributing to atherosclerotic plaque destabilization and rupture. 
Contributing to plaque destabilization, coronary artery calcification (CAC) 
involves a shift to an osteogenic phenotype. We recently found that CAC can be 
detected with positron emission tomography measurement of 18F-sodium fluoride 
combined with computed tomography in the coronary arteries much earlier than 
previously reported (233). The amount of early CAC is correlated with early intravascular 
ultrasound (IVUS) measurements of CAD progression. Early, “spotty” microcalcification 
is associated with atherosclerotic plaque instability, due to increased incidence of 
microfractures within the lesion (234-236). Aikawa et al. (234) demonstrated that early-
stage CAC is spatially associated with inflammation markers, while late-stage 
calcification does not demonstrate the same association. In an editorial associated with 
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the Aikawa study (237), Shanahan proposes a model in which early inflammation 
triggers apoptotic and osteogenic transition of CSM. Later, macrocalcifications engulf 
inflammatory regions, halting the inflammatory process and resulting in calcified, fibrotic, 
acellular plaques which are ultimately resistant to rupture. Thus, the early stages of CAC 
are when atherosclerotic plaques are most susceptible to rupture, and are therefore a 
crucial area of investigation.  
Early studies of CAD identified the presence of extracellular matrix vesicles in 
calcified arteries using electron microscopy (238; 239). However, until quite recently, it 
was unknown whether these vesicles were derived from membrane budding or through 
an exosomal pathway. Recently, however, exosomal pathways were identified in the 
formation of calcifying extracellular matrix vesicles (56). A recent review by Kapustin and 
Shanahan (240) summarizes the process of CAC. Under normal physiologic conditions, 
vesicles produced by CSM contain calcification inhibitors, such as fetuin-A (241), while 
matrix vesicles released by osteogenic CSM lack these inhibitors (240). The formation of 
calcifying matrix vesicles is associated with large elevations in cytosolic Ca2+ (239). 
Thus, it is conceivable that alterations in intracellular Ca2+ handling mechanisms could 
contribute to the osteogenic phenotype. In chapter two of this work, we demonstrated 
that SR Ca2+ stores and SERCA activity are reduced in late-stage CAD. Ca2+ store 
depletion due to decreased SERCA activity may contribute to compensatory rises in 
cytosolic Ca2+ through constitutive activation of SOCE mechanisms.  
To examine the dual role of SR Ca2+ store depletion and activation of SOCE in 
induction of CAC, future studies will include the culture of arterial rings in media 
containing elevated phosphate as an initial substrate for calcification. Chronic SR Ca2+ 
store depletion may be attained through continued blockade of SERCA function with 
cyclopiazonic acid (CPA). TRPC1 expression and SOCE may be assessed in the 
manner previously described. Calcification may be measured histologically by Von 
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Kossa staining. Additionally, OsteoSense 680EX may be employed to detect early 
deposition of hydroxyapatite, as demonstrated by Aikawa et al. (234). Chronic depletion 
of SR Ca2+ and the subsequent activation of SOCE is hypothesized to increase 
deposition of hydroxyapatite. Additionally, knockdown of TRPC1 expression is 
hypothesized to result in reduced hydroxyapatite deposition. In contrast to the elevations 
in both SR and cytosolic Ca2+ associated with proliferation, the proposed model for 
calcification describes a depleted SR Ca2+ store concurrent with increases in cytosolic 
Ca2+  
Induction of both CSM proliferation and CAC requires elevations in cytosolic 
Ca2+. In the model described in Fig. 5.2, the elevated SR Ca2+ load contributes to 
increased cytosolic Ca2+ through SOCE following SR Ca2+ unloading. Concurrently, 
elevations in SERCA activity may prevent cytosolic Ca2+ from attaining the level of 
“overload” necessary for formation of calcific matrix vesicles and induction of CAC (239; 
242; 243). Thus, both increased and decreased SERCA function may contribute to 
increases in cytosolic Ca2+ through SOCE-dependent mechanisms. However, the 
direction of SERCA regulation (up- vs. down-) may serve as a molecular switch, 
determining the level of cytosolic Ca2+ overload, thereby driving the transition from 
proliferative to osteogenic CSM.  
If reductions in SERCA activity serve as a molecular switch for the proliferative-
to-osteogenic transition, then it is necessary to ask what may drive the reduction in 
SERCA activity. SERCA function is reduced by the enrichment of the SR membrane with 
cholesterol (244; 245). Under normal, healthy conditions, the SR membrane contains 
little to no cholesterol (245; 246). However, recent studies suggest that CSM within 
atherosclerotic lesions may take up cholesterol and become foam cells (43; 247). 
Indeed, recent lineage tracing studies indicate that proliferative CSM within 
atherosclerotic lesions transition to macrophage-like cells capable of taking up oxidized 
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lipoproteins (248-250). Cholesterol uptake by macrophage-like cells results in 
enrichment of SR membrane with cholesterol, and subsequent inhibition of SERCA 
(244). Correspondingly, there is ample literature evidence that chronically elevated low-
density lipoprotein (LDL) cholesterol increases risk of CAC (251-256). More specifically, 
apolipoprotein B has been associated with increased CAC (257). Taken together, these 
data suggest that chronic exposure to elevated LDL results in the uptake of oxidized LDL 
by CSM, thereby inhibiting SERCA function and inducing calcifying matrix vesicle 
formation. Future studies should examine CSM SERCA function and incidence of 
calcification in arterial segments cultured in the presence and absence of oxidized LDL. 
These studies could provide mechanistic background for interactions between the 
dyslipidemia associated with MetS, reductions in SERCA function, and induction of CAC. 
Fig. 5.3 provides an overall working model of the predicted effect of chronically elevated 
LDL on SERCA function and calcific matrix vesicle formation. 
It is also important to note that, concurrently with elevated SERCA and SOCE, 
VGCC activity is also elevated. While the impetus for increased VGCC activity remains 
unknown, Berwick et al. (76) demonstrated that the elevated VGCC activity contributes 
to the increased coronary arterial tone observed in early CAD. Additionally, while VGCC 
activity is elevated in early CAD (187), blockade of VGCCs with diltiazem does not alter 
CSM proliferation (72). Indeed, VGCC activity is associated with maintenance of a 
differentiated, contractile phenotype (258), promoting smooth muscle myosin heavy 
chain expression (179). Thus, increased VGCC activity is unlikely to contribute to the 
proliferative phenotype modulation, and is likely highly pathogenic, contributing to 
increased vasoconstriction observed in early CAD. Further studies are necessary to 
determine whether VGCC activity is localized to microdomains within the sarcolemma, 
which may contribute to its unique effects during early CAD, when other Ca2+ handling 
proteins are promoting the proliferative phenotype transition. Similar phenomena have 
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been observed in neurons where N-type and L-type VGCCs are relegated to separate 
membrane domains, thus participating in “private lines of communication” and serving 
different roles in neuronal cell signaling (259; 260). Regarding a putative impetus for 
elevations in VGCC function, Ossabaw swine demonstrate elevated aldosterone 
secretion with MetS induction (186). Spironolactone, an aldosterone antagonist, inhibits 
VGCC activity (261). Correspondingly, aldosterone treatment of rat cardiomyocytes with 
aldosterone resulted in increased Ca2+ current which was prevented with spironolactone 
(262). Thus, increased VGCC activity is likely induced directly by the MetS “milieu” in 
Ossabaw swine. 
Closing Remarks 
 This dissertation supports an overall working model: During MetS-induced CAD, 
initial increases in SERCA function drive SOCE-mediated elevations in cytosolic Ca2+, 
which contributes to CSM proliferation in a compensatory and protective fashion. Long 
term elevations in LDL cholesterol trigger the uptake of LDL by proliferative CSM 
residing in the atherosclerotic lesion, resulting in cholesterol enrichment in the SR 
membrane. Loading of the SR membrane with cholesterol inhibits SERCA function. 
Reduced SERCA function results in a depleted SR Ca2+ store, which drives further 
SOCE and results in cytosolic Ca2+ overload. To compensate for cytosolic Ca2+ overload, 
matrix vesicles are loaded with Ca2+ and other calcifying components and released into 
the extracellular matrix, thus contributing to the induction of CAC. 
 CSM phenotypic modulation during atherosclerotic CAD progression is complex. 
Until recently, only two aberrant CSM phenotypes had been identified: proliferative CSM 
and osteogenic CSM. More recently, however, lineage tracing studies have expanded 
our understanding of the complexity of CSM modulation within atherosclerotic plaques, 
adding an additional phenotype – that of macrophage-like CSM which demonstrate 
impaired cholesterol transport (247), possibly contributing to plaque growth and 
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progression. As we have here described, a number of CSM Ca2+ handling processes are 
perturbed during CAD progression. We have established increased SERCA function as 
a causal factor in CSM proliferation. However, the role of reduced SERCA function and 
well as previously observed alterations in VGCC function, SOCE, and Ca2+ extrusion 
mechanisms in CSM phenotypes has yet to be explored. These alterations in CSM Ca2+ 
may be protective/adaptive or detrimental. Further elucidation of the protective vs. 
detrimental nature of alterations in CSM Ca2+ regulation will enhance our understanding 
of the specific mechanisms underlying CAD progression, and will allow fine-tuning of 
patient treatment and care.  
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Figures 
 
Figure 5.1: CSM phenotypic modulation during CAD progression. Healthy coronary 
arteries contain primarily contractile CSM. Increases in SERCA function result in 
elevated SR Ca2+ stores, driving the switch to the proliferative CSM phenotype. Later, 
reductions in SERCA function and SR Ca2+ store results in further modulation to 
additional phenotypes. During CAD progression, CSM fail to respond to GLP-1 receptor-
mediated actions on SERCA activity. SR = Sarcoplasmic reticulum. Blue dots = Ca2+.  
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Figure 5.2: Elevated SERCA function drives CSM proliferation. Increased SERCA 
function in early CAD results in SR Ca2+ store overload, triggering SR Ca2+ unloading via 
RyR and/or IP3R-mediated Ca2+ release, thereby activating SOCE through TRPC1. 
Chronically elevated SR and cytosolic Ca2+ contribute to expression of cell cycle proteins 
and secretion of extracellular matrix proteins, such as collagen and elastin. TRPC1 = 
Transient receptor potential canonical 6 channel; CaC = Cytosolic Ca2+; IP3R = Inositol 
1,4,5-trisphosphate receptor; SERCA = Sarco-endoplasmic reticulum Ca2+ ATPase; RyR 
= Ryanodine receptor; SR = Sarcoplasmic reticulum; CaSR = SR Ca2+; Nuc = Nucleus. 
  
 95 
 
Figure 5.3: Chronic exposure to LDL results in CSM uptake of cholesterol, driving 
coronary artery calcification. Uptake of cholesterol by CSM results in enrichment of 
the SR membrane with cholesterol, functionally inhibiting SERCA activity. Drastic 
depletion of the SR Ca2+ store results in constitutive activation of SOCE mechanisms, 
resulting in cytosolic Ca2+ overload and loading of matrix vesicles. Secretion of matrix 
vesicles results in deposition of hydroxyapatite crystals in the extracellular matrix. 
TRPC1 = Transient receptor potential canonical 1 channel; CaC = Cytosolic Ca2+; IP3R = 
Inositol 1,4,5-trisphosphate receptor; SERCA = Sarco-endoplasmic reticulum Ca2+ 
ATPase; RyR = Ryanodine receptor; SR = Sarcoplasmic reticulum; CaSR = SR Ca2+; Nuc 
= nucleus. 
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APPENDIX A 
 
PROTOCOL FOR DISPERSION OF VASCULAR SMOOTH MUSCLE CELLS (VSM) 
Michael Sturek Ph.D, MLM, 8/19/13, MLM SLD, 07/25/14 
Current Date        -       -             Initials_______       
 1. Conduit coronary arteries of swine are typically used.  The artery is classified as 
proximal, middle, and distal thirds. At euthanasia/tissue collection, grossly dissect 
vessels by first locating vessel and then making a transverse cut through myocardium 
near ostium. Remove entire length of conduit artery with minimal adjacent cardiac 
muscle, fat, etc. attached. Place the tissue into wide-mouth bottle containing ~50-75 ml 
ice-cold 2CaNa. Place immediately into cooler filled with ice. (NOTE: in the case of 
overnight transport, store tissue in EH storage media on ice). 
[Animal: Pig#               , Age             , Time dead                , Misc.                  ] 
[Portion of artery:  Proximal      , Middle      , Distal         
Artery:  LAD___ RCA        CFX       Other?________]  
[Date         -        -        , Time of storage           ] 
 2.  Clean artery of adherent connective tissue, fat, cardiac muscle, etc. in cell culture 
hood in 100 x 20 mm culture dish in ~30 ml Low Ca. Treat artery gently (do not stretch 
excessively, if possible). 
**At this point, the artery can be stored in the refrigerator in storage media for 2-5 
days, if necessary. 
[Storage media = EH + PS] 
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[In refrigerator:  Date         -        -          Time           ] 
 3.  Cut open artery longitudinally to reveal lumen. Pin down the artery with the lumen 
facing up in a 30 ml Sylgard jar with 2 mL Collagenase solution. (Approximately a 1 cm2 
area of vessel is enough to yield several million SMC.) Pin the artery segment on all 
corners and at the middle to increase surface area.   
 4. Place jar in 37° C shaking water bath (100 strokes/min; 5.5 on dial) for 60 min. The 
jar should be placed so that the long axis of the vessel segment is parallel with the 
direction of the shaking. 
[Collagenase batch:  Date made:         -        -        , Made by:                          ] 
[Dispersion 1:  Date         -        -        ,  
Time started                     , Time ended                     ] 
5.  Aspirate supernatant and pipette over artery several times to loosen isolated CSM. 
Place drop of supernatant in 35 mm petri dish on microscope and observe. (At this point 
expect mostly connective tissue, endothelial cells (EC), etc., but few CSM. EC are round 
and clump together in bunches). Note appropriately and either: 1) discard_____, 2) save 
in 15 ml tube for immediate fura-2 or patch-clamp studies_____. If #2, transfer 
supernatant to 15 mL conical tube and clearly label with pig number and cell fraction. 
Centrifuge at 900 rpm (Not RCF) for 4 min, remove supernatant (Be careful not to 
aspirate the pellet!), then re-suspend pellet in 1 mL of freshly prepared 0.02%BSA in 
2CaNa (20 mg BSA/10 mL 2CaNa). Add 2.5μL fura-2 AM and triturate several times. 
Place in 37° C water bath for ~30-45 mins.  
 Cell fraction: ______________ (Ignore this section if discarded) 
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[Dye: Fura-2____, Other_____ Dye concentration               ]  
[Loading:  Date         -        -        ,  
Time started                , Time ended                      ] 
6.  Add another 2 mL Collagenase solution to Sylgard jar and repeat steps 4 and 5 until 
isolation is complete.  
 Step 4: 
 [Dispersion 2:  Time started                      , Time ended                      ] 
 Step 5: 
  Cell fraction: ______________ 
 [Dye: Fura-2____, Other_____ Dye concentration               ]  
 [Loading:  Date         -        -        ,  
 Time started                , Time ended                      ] 
 Step 4: 
 [Dispersion 3:  Time started                      , Time ended                      ] 
 Step 5: 
  Cell fraction: ______________ 
 [Dye: Fura-2____, Other_____ Dye concentration               ]  
 [Loading:  Date         -        -        ,  
 Time started                , Time ended                      ] 
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7. Centrifuge cells at 900 rpm for 4 min, re-suspend in EH solution and put in 37° C 
water bath for ~20 min.  
 [Time started                , Time ended                      ] 
8. Centrifuge cells at 900 rpm for 4 min, re-suspend in 0.02%BSA in 2CaNa and chill on 
ice. Wrap tubes in foil to protect from light exposure.  
NOTES: 
1. All steps following fura-2 loading, CSM are light-sensitive. When possible, 
minimize exposure to light.  
2. "Overnight dispersion" - It is also possible to disperse by exposing cells to 2 mL 
collagenase in bottle at room temp. for »8-10 hours. 
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APPENDIX B 
EXPERIMENTAL SOLUTIONS 
8-20-13                                             Collagenase (in Low Ca) 
 
Component 
 
Concentration 
 
20 ml tot. 
 
10 ml tot. 
 
Stock 
Collagenase, 
CLS II 
300 U/mL 20 mg 10 mg 
300 U/mg 
(04-12-12, Worthington) 
BSA (Fraction V) 0.2% (wt/vol) 40 mg 20 mg (09-94, Sigma-Aldrich) 
Soybean Trypsin 
Inhibitor Type SI 
0.1% 20 mg 10 mg 
2.17 mg trypsin/mg 
(03-04-14, Worthington) 
DNase I, Type IV 459 KUnitz/mL 4 mg 2 mg 
2297 KUnitz/mg 
(06-04-14, Sigma-Aldrich) 
 
[Batch:  Date made:         -        -        , Made by:                                          ] 
1.  Adjust pH of Low Ca to 7.55, then add collagenase and pH will be exactly 7.40 filter. 
2.  Make in 10-20 ml quantities. Each isolation requires at least 4-6 ml collagenase. 
Remaining collagenase solution may be frozen at -20° C for up to 10 days. 
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8-3-14                                         2 CaNa 
 
 Components 
 
 Conc. (mM) 
 
 1000 ml total 
 
CaCl2 
 
2 
 
20 ml of 0.1 M 
 
NaCl 
 
138 
 
138 ml of 1.0 M 
 
MgCl2 
 
1 
 
10 ml of 0.1 M 
 
KCl 
 
5 
 
5 ml of 1.0 M 
 
HEPES 
 
10 
 
10 ml of 1.0 M 
 
Glucose 
 
10 
 
1.8 g 
 
pH (with NaOH) 
 
7.4 
 
3-4 ml of 1.0 M 
 
NOTES: 
1. Sterile solutions all contain PS and are sterilized by filtration through Millex-GS 0.2 
μm filter or Millipore Stericup apparatus.  
2. Penicillin Streptomycin (PS) 100 mg/ml (100 U/ml) is added in a 1:100 (vol:vol) ratio 
to yield a 1% PS solution. 
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7-9-87                                             Low Ca 
 
 Components 
 
 Concentration (mM) 
 
 1000 ml total 
CaCl2 0.5 5.0 ml of 0.1 M 
NaCl 135 135 ml of 1.0 M 
MgCl2 1 10 ml of 0.1 M 
KCl 5 50 ml of 0.1 M 
KH2PO4 0.44 4.4 ml of 0.1 M 
Na2HPO4 0.34 3.4 ml of 0.1 M 
NaHCO3 2.6 26 ml of 0.1 M 
Amino Acids 1X 20 ml of 50X 
Vitamins 1X 10 ml of 100X 
Phenol Red 0.001% 2 ml of 0.5% 
HEPES 20 20 ml of 1.0 M 
Glucose 10 1.8 g 
pH 7.4 with NaOH 
PS 1% 10 ml 
NOTES: 
 1.  Low Ca is exactly like EH, except that the Ca concentration is only 0.5 mM, and no 
horse serum is used. 
 2.  Low Ca with horse serum may be used to facilitate acquisition of a seal when doing 
patch-clamp studies. 
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 7-9-87                            EH (aka Storage media) 
 
 Components 
 
 Concentration (mM) 
 
 1000 ml total 
CaCl2 2.0 20 ml of 0.1 M 
NaCl 135 135 ml of 1.0 M 
MgCl2 1 10 ml of 0.1 M 
KCl 5 50 ml of 0.1 M 
KH2PO4 0.44 4.4 ml of 0.1 M 
Na2HPO4 0.34 3.4 ml of 0.1 M 
NaHCO3 2.6 26 ml of 0.1 M 
Amino Acids 1X 20 ml of 50X 
Vitamins 1X 10 ml of 100X 
Phenol Red 0.001% 2 ml of 0.5% 
HEPES 20 20 ml of 1.0 M 
Glucose 10 1.8 g 
pH 7.4 with NaOH 
PS 1% 10 ml 
Horse Serum 2% 20 ml 
NOTES: 
 1. EH media is a type of Eagle's Minimal Essential Medium (EMEM), but also has 
HEPES as a pH buffer, so that bubbling the solution with O2 is not necessary for 
maintenance of pH. 
  2. Sterile-filter under laminar flow hood with Millipore Stericup system.  
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8-4-14                                           2Ca80K 
 
 Components 
 
 Conc. (mM) 
 
 1000 ml total 
 
CaCl2 
 
2 
 
20 ml of 0.1 M 
 
NaCl 
 
63 
 
63 ml of 1.0 M 
 
MgCl2 
 
1 
 
10 ml of 0.1 M 
 
KCl 
 
80 
 
80 ml of 1.0 M 
 
HEPES 
 
10 
 
10 ml of 1.0 M 
 
Glucose 
 
10 
 
1.8 g 
 
pH (with NaOH) 
 
7.4 
 
3-4 ml of 1.0 M 
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2-29-16                                           0CaNa 
 
 Components 
 
 Conc. (mM) 
 
 1000 ml total 
 
CaCl2 
 
---- 
 
---- 
 
NaCl 
 
138 
 
138 ml of 1.0 M 
 
MgCl2 
 
1 
 
10 ml of 0.1 M 
 
KCl 
 
5 
 
5 ml of 1.0 M 
 
HEPES 
 
10 
 
10 ml of 1.0 M 
 
KEGTA 
 
10-5 M 
 
1 ml of 0.01 M 
 
Glucose 
 
10 
 
1.8 g 
 
pH (with NaOH) 
 
7.4 
 
5-7 ml of 1.0 M 
 
NOTES:  
1. Rationale for low [Ca2+] – Determination of the importance of extracellular Ca2+ 
(presumably Ca2+ influx) for a measured increase in intracellular Ca2+. 
2. CaCl2 removal does not include equimolar addition of MgCl2 or other ions. We 
have only used 1 and 5 mM EGTA on cells when achieving a fura-2 RATIO 
minimum. The cells probably become very leaky to Na+ and other ions, thus 
addition of Mg2+ would “stabilize” the membrane. 
3. Total ml of NaOH added gives number of mM extra Na added; e.g. total [Na+] for 
0CaNa is ~ 143 mM. Note that NaCl increases to 127 mM with –CaNa, 5 EGTA 
solution to keep [Na+; at 143 mM as ~16 mM Na+ used for pH. 
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8-4-14                                           2Ba80K5Na 
 
Components 
 
Conc. (mM) 
 
1000 ml total 
 
BaCl2 
 
2 
 
20 ml of 0.1 M 
 
LiCl 
 
63 
 
63 ml of 1.0 M 
 
MgCl2 
 
1 
 
10 ml of 0.1 M 
 
KCl 
 
80 
 
80 ml of 1.0 M 
 
HEPES 
 
10 
 
10 ml of 1.0 M 
 
Glucose 
 
10 
 
1.8 g 
 
pH (with NaOH) 
 
7.4 
 
3-4 ml of 1.0 M 
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APPENDIX C 
PROTOCOL FOR ORGAN CULTURE OF SWINE CORONARY ARTERY RINGS TO 
INDUCE MEDIAL THICKENING 
Mikaela McKenney, Umut Ulge, 07/23/14. Modified, Stacey D. Rodenbeck, 03/22/16 
1. Euthanasia per standard protocol. With sterile gloves and tools, remove heart 
with pericardial sac intact. 
2. Lay heart on inside of paper from sterile glove pack and remove pericardial sac 
with sterile tools. 
3. Thoroughly rinse the heart with ice cold sterile-filtered 2CaNa + 2% 
penicillin/streptomycin (P/S). 
4. Grossly dissect the coronary arteries and place in individual appropriately pre-
labeled tubes of 2CaNa + 2% P/S. Keep tubes on ice. 
5. Transfer collected specimens to lab on ice for dissection under the sterile laminar 
flow hood. 
6. Open the flow hood and turn off U.V. light. Clean surface with 70% ethanol. 
7. Thaw a frozen aliquot of 50 mL sterile-filtered Low Ca solution for fine dissection. 
8. In flow hood, remove grossly dissected artery and place in Low Ca solution in a 
sterile culture dish on ice. Finely dissect coronary artery from myocardium and 
adventitia carefully and gently. 
9. Allow clean artery to rest in ice cold Low Ca solution while preparing a 6-well 
plate with 4-5 mL of sterile phosphate-buffered saline (PBS) in each well. 
10. Section cleaned artery into rings of 2-4 mm in length, and place in top left well of 
prepared 6-well plate. 
11. Allow rings to sit in PBS for ~30 seconds, and then transfer clockwise to the next 
well. Transfer each ring separately and allow excess solution to drip off of the 
ring into the previous well before transfer. Continue to transfer rings in a 
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clockwise fashion until all rings have undergone complete 6-well serial 
“sterilization.” 
12. Prepare a 12-well plate for culture by filling each well with 2 mL of culture media 
(Dulbecco’s Modified Eagle’s Medium (DMEM) + 180 mg/dL glucose + 1% P/S + 
20% fetal bovine serum). 
13. Set aside arterial segments for cold stored controls. 
14. Transfer a single coronary segment into a single well of the prepared 12-well 
plate. 
15. Cover each plate and label appropriately with pig number, date, and culture 
conditions. 
16. Transfer plates to the 37°C incubator. Check that the CO2 is set to 4.6% and that 
the tray at the bottom of the incubator is full of distilled water. 
17. Change culture media every two days. 
18. Culture rings for 7 days to achieve optimal medial thickening. 
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APPENDIX D 
QUANTIFICATION OF MEDIAL AREA IN VERHOEFF VAN-GIESON STAINED 
CORONARY ARTERIES IN ADOBE PHOTOSHOP CS6 
Stacey D. Rodenbeck, 03/22/16 
1. Open image of Verhoeff Van-Gieson stained artery (taken with 10X microscope 
objective) in Adobe Photoshop CS6. 
2. Ensure that the measurement log is open: Window > Measurement Log. 
3. To set scale: Image > Analysis > Set Measurement Scale > Custom 
a. The ruler tool is automatically selected for this activity. To set pixel length, 
trace the length of the scale bar. 
b. Type in scale bar length in micrometers (ie: 500) for logical length. 
c. Click OK. 
4. Select magnetic lasso tool. Click once at any point along external elastic lamina 
(EEL) to begin tracing. Release, and drag around the external elastic laminar 
border. Click to close circle. 
5. Click “Record Measurements” in measurement log. 
6. Record “Area” value in Excel Spreadsheet as EEL Area. 
7. Repeat steps 4-6, tracing along the internal elastic lamina (IEL). 
8. Medial area = EEL Area – IEL Area 
9. To normalize medial area to artery size, calculate % Medial Area = (Medial 
Area/EEL Area)*100. 
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APPENDIX E 
QUANTIFICATION OF MEDIAL COLLAGEN IN MASSON’S TRICHROME STAINED 
CORONARY ARTERY SEGMENTS 
Stacey D. Rodenbeck, 03/22/16 
1. Open image of Masson’s Trichrome stained artery (taken with 10X microscope 
objective) in Adobe Photoshop CS6. 
2. Ensure that the measurement log is open: Window > Measurement Log. 
3. To set scale: Image > Analysis > Set Measurement Scale > Custom 
a. The ruler tool is automatically selected for this activity. To set pixel length, 
trace the length of the scale bar. 
b. Type in scale bar length in micrometers (ie: 500) for logical length. 
c. Click OK. 
4. Make a “Background copy” as a new layer by right-clicking on “Background” and 
selecting “Duplicate Layer.” Name this layer “Adventitia”. 
5. Working from the “Adventitia” layer, select the magnetic lasso tool, and trace 
along inner border of the blue adventitia, then Ctrl-X (cut) and Ctrl-V (paste) to 
create a new layer containing the medial layer. 
6. Change name of new layer to “Media.” 
7. In the “Media” Layer, use the magnetic lasso to trace the inner border of the 
media, and click “Delete,” leaving only the media in view. 
8. Select both “Adventitia” and “Media” layers concurrently. Using the Magic wand 
tool, set “tolerance” to 20, and select “Sample All Layers.” Click in Adventitia to 
select blue in both layers. You may add to the selected area by holding down 
“Shift” as you click. 
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9. Once you are satisfied that you’ve selected all of the collagen in both layers, click 
“Record Measurements” in the measurement log. Record the area measure 
under “Total Collagen Area” in an Excel file. 
10. Deselect the “Media” layer. 
11. Working with the “Adventitia” layer only, use the Magic Wand tool to select the 
adventitial collagen again. Be especially careful to ensure that you select the 
same amount of the adventitia as you did in step 9. 
12. Click “Record Measurements.” 
13. Record area measure under “Adventitial Collagen Area” in Excel File. 
14. Medial Collagen Area = Total Collagen Area – Adventitial Collagen Area. 
15. Deselect “Adventitia” layer. 
16. Select “Media” layer.  
17. Determine medial area by using magic wand tool to click outside of the media. 
Everything that is not media will be selected. Type Ctrl-shift-I to select the 
inverse. 
18. Click “Record Measurement.” 
19. Record Area measure as “Medial Area” in Excel file. 
20. To express collagen content as a percentage of medial area, % Medial Collagen 
= (Medial Collagen Area/Medial Area)*100. 
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APPENDIX F 
QUANTIFICATION OF POSITIVE KI-67 STAINED CELLS IN ADOBE PHOTOSHOP 
CS6 
Stacey D. Rodenbeck, 03/22/16. 
1. Open image of Ki-67 stained artery segment (taken with 40X microscope 
objective) in Adobe Photoshop CS6. 
2. Ensure that the measurement log is open: Window > Measurement Log. 
3. To set scale: Image > Analysis > Set Measurement Scale > Custom 
a. The ruler tool is automatically selected for this activity. To set pixel length, 
trace the length of the scale bar. 
b. Type in scale bar length in micrometers (ie: 25) for logical length. 
c. Click OK. 
4. Cell nuclei positively stained with Ki-67 will be brown. Manually count these, and 
record the count in an Excel spreadsheet as “Ki-67 Nuclei” 
5. Select “Channels” in the right tool bar. 
6. Click through the Red, Green, and Blue channels to determine which two 
channels show the most contrast between them (usually red and blue). 
7. Image > Calculations 
a. There will be two sources. Set the channel 1 to “Red” and channel 2 to 
“blue. 
b. Under “blending” select “subtract.” 
c. Adjust the “offset” so that all cell nuclei are white (usually -110). 
d. Click OK. 
8. A new channel will have been created. Label this channel “Nuclei.” 
9. With the Nuclei channel selected, Image > Adjustments > Threshold.  
a. Set threshold such that all nuclei are white and background is black. 
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10. To minimize noise from small particles, Filter > Noise > Median 
a. Adjust “radius” to eliminate smaller particles (usually 5-10). 
11. Using the magic wand tool, select white nuclei.  
12. Click “Record Measurements” 
13. Record “Count” in Excel spreadsheet as “Total Nuclei.” 
14. % Positive Nuclei = (Ki-67 Nuclei/Total Nuclei)*100. 
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2012 Indiana University School of Medicine Graduate Division University Fellowship 
2014 Indiana Physiological Society Presentation Award 
2014 Moenkhaus Physiology Graduate Fellowship for Academic Excellence, Indiana 
University School of Medicine; Department of Cellular & Integrative 
Physiology 
2016 Society for Experimental Biology and Medicine Young Investigator Award 
Grant Support 
AHA 15PRE25280001: Midwest Affiliate Winter 2015 Predoctoral Fellowship, 
American Heart Association; 2015-Present. 
TEACHING EXPERIENCE 
Lectures 
Fall 2013 
BIOL L101Introduction to Biological Sciences, Indiana University Southeast 
     “Circulatory Systems” 
 
Spring 2013 
 BIOL L101 Introduction to Biological Sciences, Indiana University Southeast 
     “Circulatory Systems” 
 
 BIOL 55700 Physiology II, Indiana University Purdue University Indianapolis 
     “Physiology of Circulation” 
 
Fall 2014 
 BIOL L317 Developmental Biology, Indiana University Southeast 
     “The Third Week of Development” 
     “Cardiovascular System Development” 
 
 PHSL F503 Human Physiology, Indiana University School of Medicine 
     “Cardiovascular System Design” 
     “ECG and the Cardiac Cycle” 
     “Cardiac Output” 
   
 
  
Teaching/Laboratory Assistantships 
Spring 2014 
 GRAD G735 Cardiovascular, Respiratory, and Renal Physiology 
Teaching Assistant, ECG Analysis,  
Indiana University School of Medicine  
Indianapolis, IN 
 Medical Physiology 
Teaching Assistant, ECG Analysis,  
Indiana University School of Medicine 
Indianapolis, IN 
 
Spring 2015 
 Medical Physiology 
     Teaching Assistant, ECG Analysis,  
Indiana University School of Medicine,  
Indianapolis, IN 
 GRAD G735 Cardiovascular, Respiratory, and Renal Physiology 
     Teaching Assistant  
Indiana University School of Medicine  
Indianapolis, IN 
 
Service/Outreach 
January 2013: Student Ambassador; IBMG recruitment weekend, Indiana University 
School of Medicine Graduate Division, Indianapolis, IN 
 
January 2014: Student Ambassador; IBMG recruitment weekend, Indiana University 
School of Medicine Graduate Division, Indianapolis, IN 
 
January 2014: Science fair judge; St. Malachy Science Fair, St. Malachy School, 
Brownsburg, IN 
 
February 2014: Student Ambassador; IBMG recruitment weekend, Indiana 
University School of Medicine Graduate Division, Indianapolis, IN 
 
August 2014: Student Mentor; IBMG new student orientation, Indiana University 
School of Medicine Graduate Division, Indianapolis, IN 
 “Think, Talk, Study Like a Graduate Student” (In collaboration with Gail Gardiner) 
 
October 2014: Panelist; Graduate School Panel Discussion, Department of Biology; 
School of Natural Sciences; Indiana University Southeast 
 
January 2015: Science fair judge; St. Malachy Science Fair, St. Malachy School, 
Brownsburg, IN 
 
January 2015: Student Ambassador; IBMG recruitment weekend, Indiana University 
School of Medicine Graduate Division, Indianapolis IN 
 
February 2015: Student Ambassador; IBMG recruitment weekend, Indiana 
University School of Medicine Graduate Division, Indianapolis, IN 
 
 
  
Mentoring 
Summer, 2014: Medical Student, Summer Research Program, Indiana University 
School of Medicine, Indianapolis, IN 
 
Spring, 2015: Ph.D. Rotation Students (3), IBMG Program, Indiana University 
School of Medicine, Indianapolis, IN 
 
Spring, 2015: Masters Student, Department of Cellular & Integrative Physiology, 
Indiana University School of Medicine, Indianapolis, IN 
 
Summer, 2015: Ph.D. Rotation Student, Biomedical Engineering Department, 
Purdue University, West Lafayette, IN 
 
PROFESSIONAL ORGANIZATIONS 
 
Memberships 
Indiana Physiological Society, 2013-present 
American Physiological Society, 2013-present 
Society for Experimental Biology and Medicine, 2013-present 
 
PUBLICATIONS 
 
Manuscripts 
1) Yoder SM, Dineen SL, Wang Z, Thurmond DC. YES, a SRC Family Kinase, Is a 
Proximal Glucose-specific Activator of Cell Division Cycle Control Protein 42 
(Cdc42) in Pancreatic Islet β Cells. JBC 286(16):11476-87. 2014. 
 
2) Dineen SL, McKenney ML, Bell LN, Fullenkamp AM, Schultz KA, Alloosh M, 
Chalasani N, Sturek M. Metabolic syndrome abolishes glucagon-like peptide-1 
receptor agonist stimulation of SERCA in coronary smooth muscle. Diabetes 
64(9):3321-27. 2015. 
Highlighted with full commentary: Davies MG, New Insights on the Role of 
SERCA During Vessel Remodeling in Metabolic Syndrome. Diabetes 64(9):3066-
68. 2015. 
3) McKenney-Drake ML*, Rodenbeck SD*, Owen MK, Schultz KA, Tune JD, Sturek 
M. Biphasic alterations in coronary smooth muscle Ca2+ regulation in a repeat 
cross-sectional study of coronary artery disease severity in metabolic syndrome, 
Atherosclerosis 2016 (In Press). 
 
4) McKenney-Drake ML*, Rodenbeck SD*, Owen MK, Schultz KA, Tune JD, Sturek 
M. Repeat cross-sectional data on the progression of the metabolic syndrome in 
Ossabaw miniature swine, Data in Brief 2016 (In Press). 
 
5) Rodenbeck SD*, Zarse CA*, McKenney-Drake ML, Bruning RS, Sturek M, Chen 
NX, Moe SM. Disrupted intracellular calcium homeostasis of vascular smooth 
muscle cells in a rat model of chronic kidney disease, (Under Review). 
 
6) Rodenbeck SD, Barnard AL, Sturek M. SERCA activator CDN1163 induces 
coronary smooth muscle proliferation in an organ culture model of coronary 
artery disease, (In Preparation). 
  
 
7) Bruning RS, Rodenbeck SD, Alloosh M, Sturek M. Effect of metabolic syndrome 
and advancing age on vascular smooth muscle, (In Preparation). 
 
8) McKenney-Drake ML, Rodenbeck SD, Bruning RS, Yancey KW, Alloosh M, 
Sacks H, Sturek M. Removal of coronary epicardial adipose tissue attenuates 
progression of coronary artery disease in Ossabaw swine (In Preparation). 
 
Book Chapters and Reviews 
1) Dineen SL, Neeb ZP, Obukhov AG, and Sturek M. Transient receptor potential 
channels in metabolic syndrome-induced coronary artery disease. Ion Channels 
in Vascular Disease. I. Levitan and A.M. Dopico (Eds). New York, NY: Springer, 
(In Press, 2016). 
 
2) Sturek M, Dineen SL, Bruning RS and Alloosh MA. Animal research models in 
metabolic syndrome and cardiovascular disease. Compr Physiol (In prep): 2016 
 
Abstracts 
1) Dineen SL, McKenney ML, and Sturek M. An in vitro model of coronary artery 
disease and the changes in intracellular calcium regulation during its 
progression. FASEB J 27:lb652. 2013. 
 
2) Dineen SL, McKenney ML, and Sturek M. Glucagon-like peptide-1 (GLP-1) 
receptor agonist, exenatide, enhances Ca2+ buffering by SERCA in coronary 
smooth muscle cells from lean, healthy Ossabaw swine. FASEB J 28:700.3. 
2014. 
 
3) McKenney ML, Dineen SL, Noblet JN, Tune JD, and Sturek M. Increased Ca2+-
activated Ca2+ influx and impaired Ca2+ buffering in coronary smooth muscle from 
metabolic syndrome Ossabaw swine. FASEB J 28:1076.2. 2014. 
 
4) Zarse CA, McKenney ML, Dineen SL, Sturek M, Chen NX, and Moe SM. 
Intracellular Ca2+ signaling is altered in vascular smooth muscle cells (VSMC) in 
chronic kidney disease. J Am Soc Nephrol 25:232A, 2014. 
 
5) Dineen SL and Sturek M. Assessment of endoplasmic reticulum stress by 
graded sarcoplasmic reticulum Ca2+ store depletion in coronary smooth muscle. 
FASEB J 29:638.2. 2015. 
 
6) Rodenbeck SD, Barnard AL, and Sturek M. SERCA inhibition attenuates medial 
thickening in an organ culture model of coronary artery disease. FASEB J (In 
Press) 
 
 
PRESENTATIONS 
Invited Seminars 
1) Dineen SL. Top-down Cardiovascular Pathophysiology: Investigating Coronary 
Artery Disease from Whole Animal Phenotype to Intracellular Mechanism. Invited 
  
Seminar, Department of Biological Sciences, Butler University, October 2014, 
Indianapolis, IN 
 
Oral Presentations 
1) Dineen SL, McKenney ML, and Sturek M. Exenatide specifically enhances Ca2+ 
buffering by SERCA in coronary smooth muscle cells from lean, healthy 
Ossabaw swine. Oral presentation, 4th Annual Meeting of the Indiana 
Physiological Society, February, 2014, Evansville, IN 
 
2) Dineen SL, McKenney ML, and Sturek M. Exenatide specifically enhances Ca2+ 
buffering by SERCA in coronary smooth muscle cells from lean, healthy 
Ossabaw swine. Oral presentation, Indiana Academy of Science, March 2014, 
Indianapolis, IN 
 
Poster Presentations 
1) Dineen SL, Rollins JM, and Kirchner G. Determining the Source of Kanamycin 
Resistance in a Halobacillus blutaparonensis Isolate. Poster presentation, 
Indiana Academy of Science, March 2012, West Lafayette, IN 
 
2) Dineen SL, McKenney ML, and Sturek M. An in vitro model of coronary artery 
disease and the changes in intracellular calcium regulation during its 
progression. Poster presentation, 3rd Annual Meeting of the Indiana Physiological 
Society, February, 2013, Indianapolis, IN 
 
3) Dineen SL, McKenney ML, and Sturek M. An in vitro model of coronary artery 
disease and the changes in intracellular calcium regulation during its 
progression. Poster presentation, Experimental Biology 2013, Boston, MA 
 
4) Dineen SL, McKenney ML, and Sturek M. Exenatide specifically enhances Ca2+ 
buffering by SERCA in coronary smooth muscle cells from lean, healthy 
Ossabaw swine. Poster presentation, Experimental Biology 2014, San Diego, CA 
 
5) Dineen SL and Sturek M. Altered sarcoplasmic reticulum Ca2+ storage in 
coronary smooth muscle with increasing severity of coronary artery disease. 
Poster Presentation, 5th Annual Meeting of the Indiana Physiological Society, 
February, 2015, Indianapolis, IN 
 
6) Dineen SL and Sturek M. Assessment of endoplasmic reticulum stress by 
graded sarcoplasmic reticulum Ca2+ store depletion in coronary smooth muscle. 
Poster Presentation, Experimental Biology 2015, Boston, MA 
 
7) Rodenbeck SD, Barnard AL, and Sturek M. SERCA inhibition attenuates medial 
thickening in an organ culture model of coronary artery disease. Poster 
Presentation, Experimental Biology 2016, San Diego, CA 
 
